[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 32806
1. Maher MM, Mansour AH: Study of Chronic Hepatopathy in Patients With Sickle Cell Disease. Gastroenterology Res; 2009 Dec;2(6):338-343

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of Chronic Hepatopathy in Patients With Sickle Cell Disease.
  • BACKGROUND: Hepatic lesions in sickle cell disease were studied essentially in autopsy specimens.
  • We investigated chronic hepatopathy in living adults with sickle cell disease and report the clinical, biochemical, and hepatic histological findings in these patients.
  • METHODS: A total of 170 adult patients with sickle cell syndrome were prospectively investigated.
  • CONCLUSIONS: The clinical spectrum of sickle cell disease ranges from mild liver function test abnormalities to significant hepatic abnormalities with marked hyperbilirubinemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27990203.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Chronic hepatopathy / Sickle cell disease
  •  go-up   go-down


2. Kikuchi K, Lai AY, Hsu CL, Kondo M: IL-7 receptor signaling is necessary for stage transition in adult B cell development through up-regulation of EBF. J Exp Med; 2005 Apr 18;201(8):1197-203
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IL-7 receptor signaling is necessary for stage transition in adult B cell development through up-regulation of EBF.
  • Cytokine receptor signals have been suggested to stimulate cell differentiation during hemato/lymphopoiesis.
  • Here, we show that adult B cell development in IL-7(-/-) and IL-7R alpha(2/-) mice is arrested at the pre-pro-B cell stage due to insufficient expression of the B cell-specific transcription factor EBF and its target genes, which form a transcription factor network in determining B lineage specification.
  • Furthermore, enforced EBF expression partially rescues B cell development in IL-7R alpha(-/-) mice.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 2000 Mar;12(3):335-45 [10755620.001]
  • [Cites] Nature. 1999 Oct 7;401(6753):556-62 [10524622.001]
  • [Cites] J Exp Med. 2002 Sep 2;196(5):705-11 [12208884.001]
  • [Cites] Nature. 2000 Sep 21;407(6802):383-6 [11014194.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1999;64:13-20 [11232277.001]
  • [Cites] Annu Rev Immunol. 2001;19:595-621 [11244048.001]
  • [Cites] Blood. 2001 May 1;97(9):2708-15 [11313262.001]
  • [Cites] Annu Rev Immunol. 2002;20:301-22 [11861605.001]
  • [Cites] Immunity. 2003 Feb;18(2):229-41 [12594950.001]
  • [Cites] Curr Opin Immunol. 2003 Apr;15(2):158-65 [12633665.001]
  • [Cites] Nat Immunol. 2003 Aug;4(8):773-9 [12872121.001]
  • [Cites] J Exp Med. 2003 Nov 17;198(10):1495-506 [14610045.001]
  • [Cites] Nature. 2003 Dec 11;426(6967):671-6 [14668867.001]
  • [Cites] Annu Rev Immunol. 2004;22:55-79 [15032574.001]
  • [Cites] J Immunol. 2004 Apr 15;172(8):4770-8 [15067053.001]
  • [Cites] Dev Cell. 2004 Oct;7(4):607-17 [15469848.001]
  • [Cites] J Exp Med. 1994 Nov 1;180(5):1955-60 [7964471.001]
  • [Cites] J Exp Med. 1995 Apr 1;181(4):1519-26 [7699333.001]
  • [Cites] Immunity. 1995 Apr;2(4):331-9 [7719938.001]
  • [Cites] Nature. 1995 Jul 20;376(6537):263-7 [7542362.001]
  • [Cites] Immunity. 1995 Jul;3(1):147-61 [7621074.001]
  • [Cites] J Exp Med. 1996 Jan 1;183(1):187-94 [8551222.001]
  • [Cites] Cell. 1997 Jun 27;89(7):1033-41 [9215626.001]
  • [Cites] Immunity. 1997 Jul;7(1):155-62 [9252128.001]
  • [Cites] Cell. 1997 Nov 28;91(5):661-72 [9393859.001]
  • [Cites] Nature. 1998 Feb 26;391(6670):904-7 [9495344.001]
  • [Cites] J Exp Med. 1998 Aug 17;188(4):699-713 [9705952.001]
  • [Cites] Int Immunol. 1998 Sep;10(9):1367-75 [9786436.001]
  • [Cites] Immunity. 1999 Jul;11(1):21-31 [10435576.001]
  • [Cites] Immunity. 2002 Aug;17(2):117-30 [12196284.001]
  • (PMID = 15837809.001).
  • [ISSN] 0022-1007
  • [Journal-full-title] The Journal of experimental medicine
  • [ISO-abbreviation] J. Exp. Med.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI056123; United States / NCI NIH HHS / CA / R01 CA98129; United States / NIAID NIH HHS / AI / T32 AI052077; United States / NIAID NIH HHS / AI / T32 AI52077; United States / NCI NIH HHS / CA / R01 CA098129
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Ebf1 protein, mouse; 0 / Interleukin-7; 0 / Milk Proteins; 0 / Receptors, Interleukin-7; 0 / STAT5 Transcription Factor; 0 / Trans-Activators
  • [Other-IDs] NLM/ PMC2213146
  •  go-up   go-down


3. Sanz I, Anolik J: Reconstitution of the adult B cell repertoire after treatment with rituximab. Arthritis Res Ther; 2005;7(5):175-6
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reconstitution of the adult B cell repertoire after treatment with rituximab.
  • Therefore, it is of great importance to understand the mechanism of action of B cell depletion.
  • Given that the ideal consequence of B cell depletion would be the subsequent re-establishment of immunologic tolerance, a detailed analysis of the properties of the emerging repertoire will be required.

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunol Rev. 1999 Jun;169:107-21 [10450512.001]
  • [Cites] J Clin Invest. 2001 Oct;108(7):1061-70 [11581307.001]
  • [Cites] Arthritis Rheum. 2002 Jun;46(6):1554-62 [12115186.001]
  • [Cites] Curr Opin Rheumatol. 2004 May;16(3):180-5 [15103242.001]
  • [Cites] J Immunol. 1998 Jan 1;160(1):51-9 [9551955.001]
  • [Cites] Science. 2003 Sep 5;301(5638):1374-7 [12920303.001]
  • [Cites] J Immunol. 1999 Oct 15;163(8):4284-91 [10510367.001]
  • [Cites] Arthritis Rheum. 2004 Nov;50(11):3580-90 [15529346.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3647-54 [15191950.001]
  • [Cites] Arthritis Res Ther. 2005;7(4):R714-24 [15987473.001]
  • [CommentOn] Arthritis Res Ther. 2005;7(4):R714-24 [15987473.001]
  • (PMID = 16207341.001).
  • [ISSN] 1478-6362
  • [Journal-full-title] Arthritis research & therapy
  • [ISO-abbreviation] Arthritis Res. Ther.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI049660; United States / NIAID NIH HHS / AI / R37 AI049660; United States / NIAMS NIH HHS / AR / K08 AR048303; United States / NIAMS NIH HHS / AR / K08AR048303; United States / NIAID NIH HHS / AI / U19-AI56390; United States / NIAID NIH HHS / AI / U19 AI056390; United States / NIAID NIH HHS / AI / R01 AI049660-01A1; United States / NIAID NIH HHS / AI / R56 AI049660
  • [Publication-type] Comment; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD19; 0 / Antigens, CD27; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC1257443
  •  go-up   go-down


Advertisement
4. Burmeister T, Meyer C, Schwartz S, Hofmann J, Molkentin M, Kowarz E, Schneider B, Raff T, Reinhardt R, Gökbuget N, Hoelzer D, Thiel E, Marschalek R: The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group. Blood; 2009 Apr 23;113(17):4011-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group.
  • MLL translocations in adult B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) are largely restricted to the immature CD10(-) immunophenotypes.
  • MLL-AF4 is known to be the most frequent fusion transcript, but the exact frequencies of MLL aberrations in CD10(-) adult BCP-ALL are unknown.
  • We present a genetic characterization of 184 BCR-ABL(-) CD10(-) adult ALL cases (156 cyIg(-), 28 cyIg(+)) diagnosed between 2001 and 2007 at the central diagnostic laboratory of the GMALL study group.
  • [MeSH-major] Myeloid-Lymphoid Leukemia Protein / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Recombinant Fusion Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chromosomes, Human / genetics. Female. Histone-Lysine N-Methyltransferase. Humans. Male. Middle Aged. Neprilysin / metabolism. Societies, Medical

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19144982.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00198991/ NCT00199056
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / Recombinant Fusion Proteins; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


5. Alexandrova K, Griesel C, Barthold M, Heuft HG, Ott M, Winkler M, Schrem H, Manns MP, Bredehornsp T, Net M, Vidal MMI, Kafert-Kasting S, Arseniev L: Large-Scale Isolation of Human Hepatocytes for Therapeutic Application. Cell Transplant; 2005 Nov;14(10):845-853

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During the last decade, hepatocyte transplantation has been suggested as a safe and potentially effective clinical option for the treatment of acute or decompensating chronic liver failure as well as for hereditary liver disease.
  • Currently, one of the major limiting factors for clinical application is the insufficient access to suitable liver cell preparations.
  • In about 50% of the cases (n = 58) the three-step perfusion procedure has been completed with an average total cell yield of 5.9 × 109 cells per organ, the cell preparations displaying a mean viability of 64%.
  • Specific cell yields from three infantile donor livers were considerably higher.
  • No correlation between isolation efficiency and cold ischemia time or donor age was found within the adult organ donors.
  • In contrast, organs with a severe steatosis generally did not result in successful cell isolation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28849979.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cell transplantation / GMP / Hepatocyte isolation / Steatosis
  •  go-up   go-down


6. Vale AM, Tanner JM, Schelonka RL, Zhuang Y, Zemlin M, Gartland GL, Schroeder HW Jr: The peritoneal cavity B-2 antibody repertoire appears to reflect many of the same selective pressures that shape the B-1a and B-1b repertoires. J Immunol; 2010 Nov 15;185(10):6085-95

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We divided these sequences into those that contained N nucleotides (N(+)) and those that did not (N(-)) and then compared them with sequences cloned from sorted IgM(+)IgD(+) B cells from neonatal liver and both wild-type and TdT-deficient adult bone marrow.
  • We found that the PerC B-1a N(-) repertoire is enriched for the signatures of CDR-H3 sequences present in neonatal liver and shares many features with the B-1b N(-) repertoire, whereas the PerC B-1a N(+), B-1b N(+), and B-2 N(+) repertoires are enriched for adult bone marrow sequence signatures.
  • However, we also found several sequence signatures that were not shared with other mature perinatal or adult B cell subsets but were either unique or variably shared between the two or even among all three of the PerC subsets that we examined.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2000 Jul 17;192(2):271-80 [10899913.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):7773-80 [15944280.001]
  • [Cites] Annu Rev Immunol. 2001;19:595-621 [11244048.001]
  • [Cites] J Immunol. 2001 Jul 1;167(1):257-63 [11418657.001]
  • [Cites] J Exp Med. 2001 Oct 15;194(8):1141-50 [11602642.001]
  • [Cites] J Exp Med. 2002 Mar 18;195(6):771-80 [11901202.001]
  • [Cites] J Mol Biol. 2003 Dec 5;334(4):733-49 [14636599.001]
  • [Cites] J Mol Biol. 1982 May 5;157(1):105-32 [7108955.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Jul;79(13):4118-22 [6287467.001]
  • [Cites] Nature. 1983 Apr 14;302(5909):575-81 [6300689.001]
  • [Cites] Annu Rev Biochem. 1984;53:595-623 [6383201.001]
  • [Cites] J Immunol. 2005 Nov 15;175(10):6624-32 [16272317.001]
  • [Cites] Nat Immunol. 2006 Mar;7(3):293-301 [16429139.001]
  • [Cites] Nat Immunol. 2006 Mar;7(3):225-6 [16482166.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6293-8 [16606838.001]
  • [Cites] Eur J Immunol. 2006 May;36(5):1114-23 [16609926.001]
  • [Cites] Curr Opin Immunol. 2006 Jun;18(3):237-42 [16616470.001]
  • [Cites] J Exp Med. 2006 Jun 12;203(6):1567-78 [16754718.001]
  • [Cites] Nature. 1984 Oct 25-31;311(5988):727-33 [6092962.001]
  • [Cites] Curr Opin Immunol. 2007 Apr;19(2):150-5 [17303402.001]
  • [Cites] Eur J Immunol. 2007 Apr;37(4):1010-21 [17345580.001]
  • [Cites] J Immunol. 2008 Dec 15;181(12):8409-15 [19050258.001]
  • [Cites] J Immunol. 2008 Dec 15;181(12):8416-24 [19050259.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5773-8 [19307589.001]
  • [Cites] Eur J Immunol. 2009 Sep;39(9):2383-94 [19714574.001]
  • [Cites] Immunogenetics. 2010 Oct;62(10):653-66 [20714894.001]
  • [Cites] J Immunol. 2010 Nov 15;185(10):6075-84 [20956348.001]
  • [Cites] Science. 1985 Mar 29;227(4694):1597-601 [3975629.001]
  • [Cites] J Exp Med. 1985 Jun 1;161(6):1554-68 [3874257.001]
  • [Cites] Immunol Rev. 1986 Feb;89:5-30 [3081433.001]
  • [Cites] J Immunol. 1987 Jan 1;138(1):316-23 [3097149.001]
  • [Cites] J Immunol. 1988 Oct 15;141(8):2788-96 [3139765.001]
  • [Cites] Eur J Immunol. 1989 Oct;19(10):1849-54 [2583225.001]
  • [Cites] Cell. 1989 Dec 1;59(5):859-70 [2590942.001]
  • [Cites] J Exp Med. 1990 Mar 1;171(3):843-59 [2261012.001]
  • [Cites] EMBO J. 1990 Jul;9(7):2133-40 [2113468.001]
  • [Cites] J Exp Med. 1990 Nov 1;172(5):1377-90 [1700054.001]
  • [Cites] Immunol Today. 1991 May;12(5):154-9 [1715166.001]
  • [Cites] J Immunol. 1991 Dec 15;147(12):4343-50 [1753104.001]
  • [Cites] Immunol Today. 1991 Nov;12(11):420-1 [1786075.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3320-4 [1565622.001]
  • [Cites] J Exp Med. 1992 Jun 1;175(6):1449-56 [1588274.001]
  • [Cites] J Immunol. 1992 Jul 1;149(1):222-9 [1607655.001]
  • [Cites] Int Immunol. 1992 May;4(5):549-53 [1627492.001]
  • [Cites] Immunol Today. 1993 Feb;14(2):84-7; discussion 87-91 [7680563.001]
  • [Cites] Annu Rev Immunol. 1993;11:501-38 [8476571.001]
  • [Cites] EMBO J. 1995 Apr 18;14(8):1680-9 [7737121.001]
  • [Cites] FEBS Lett. 1996 Dec 9;399(1-2):1-8 [8980108.001]
  • [Cites] J Immunol. 1997 Feb 1;158(3):1175-86 [9013957.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):6657-63 [9862694.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2250-5 [10051627.001]
  • [Cites] FEBS Lett. 1999 Jul 16;455(1-2):188-97 [10428499.001]
  • [Cites] J Exp Med. 1999 Aug 16;190(4):471-7 [10449518.001]
  • [Cites] Immunity. 2000 Jul;13(1):37-45 [10933393.001]
  • (PMID = 20956345.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Databank-accession-numbers] GENBANK/ HM132462/ HM132463/ HM132464/ HM132465/ HM132466/ HM132467/ HM132468/ HM132469/ HM132470/ HM132471/ HM132472/ HM132473/ HM132474/ HM132475/ HM132476/ HM132477/ HM132478/ HM132479/ HM132480/ HM132481/ HM132482/ HM132483/ HM132484/ HM132485/ HM132486/ HM132487/ HM132488/ HM132489/ HM132490/ HM132491/ HM132492/ HM132493/ HM132494/ HM132495/ HM132496/ HM132497/ HM132498/ HM132499/ HM132500/ HM132501/ HM132502/ HM132503/ HM132504/ HM132505/ HM132506/ HM132507/ HM132508/ HM132509/ HM132510/ HM132511/ HM132512/ HM132513/ HM132514/ HM132515/ HM132516/ HM132517/ HM132518/ HM132519/ HM132520/ HM132521/ HM132522/ HM132523/ HM132524/ HM132525/ HM132526/ HM132527/ HM132528/ HM132529/ HM132530/ HM132531/ HM132532/ HM132533/ HM132534/ HM132535/ HM132536/ HM132537/ HM132538/ HM132539/ HM132540/ HM132541/ HM132542/ HM132543/ HM132544/ HM132545/ HM132546/ HM132547/ HM132548/ HM132549/ HM132550/ HM132551/ HM132552/ HM132553/ HM132554/ HM132555/ HM132556/ HM132557/ HM132558/ HM132559/ HM132560/ HM132561/ HM132562/ HM132563/ HM132564/ HM132565/ HM132566/ HM132567/ HM132568/ HM132569/ HM132570/ HM132571/ HM132572/ HM132573/ HM132574/ HM132575/ HM132576/ HM132577/ HM132578/ HM132579/ HM132580/ HM132581/ HM132582/ HM132583/ HM132584/ HM132585/ HM132586/ HM132587/ HM132588/ HM132589/ HM132590/ HM132591/ HM132592/ HM132593/ HM132594/ HM132595/ HM132596/ HM132597/ HM132598/ HM132599/ HM132600/ HM132601/ HM132602/ HM132603/ HM132604/ HM132605/ HM132606/ HM132607/ HM132608/ HM132609/ HM132610/ HM132611/ HM132612/ HM132613/ HM132614/ HM132615/ HM132616/ HM132617/ HM132618/ HM132619/ HM132620/ HM132621/ HM132622/ HM132623/ HM132624/ HM132625/ HM132626/ HM132627/ HM132628/ HM132629/ HM132630/ HM132631/ HM132632/ HM132633/ HM132634/ HM132635/ HM132636/ HM132637/ HM132638/ HM132639/ HM132640/ HM132641/ HM132642/ HM132643/ HM132644/ HM132645/ HM132646/ HM132647/ HM132648/ HM132649/ HM132650/ HM132651/ HM132652/ HM132653/ HM132654/ HM132655/ HM132656/ HM132657/ HM132658/ HM132659/ HM132660/ HM132661/ HM132662/ HM132663/ HM132664/ HM132665/ HM132666/ HM132667/ HM132668/ HM132669/ HM132670/ HM132671/ HM132672/ HM132673/ HM132674/ HM132675/ HM132676/ HM132677/ HM132678/ HM132679/ HM132680/ HM132681/ HM132682/ HM132683/ HM132684/ HM132685/ HM132686/ HM132687/ HM132688/ HM132689/ HM132690/ HM132691/ HM132692/ HM132693/ HM132694/ HM132695/ HM132696/ HM132697/ HM132698/ HM132699/ HM132700/ HM132701/ HM132702/ HM132703/ HM132704/ HM132705/ HM132706/ HM132707/ HM132708/ HM132709/ HM132710/ HM132711/ HM132712/ HM132713/ HM132714/ HM132715/ HM132716/ HM132717/ HM132718/ HM132719/ HM132720/ HM132721/ HM132722/ HM132723/ HM132724/ HM132725/ HM132726/ HM132727/ HM132728/ HM132729/ HM132730/ HM132731/ HM132732/ HM132733/ HM132734/ HM132735/ HM132736/ HM132737/ HM132738/ HM132739/ HM132740/ HM132741/ HM132742/ HM132743/ HM132744/ HM132745/ HM132746/ HM132747/ HM132748/ HM132749/ HM132750/ HM132751/ HM132752/ HM132753/ HM132754/ HM132755/ HM132756/ HM132757/ HM132758/ HM132759/ HM132760/ HM132761/ HM132762/ HM132763/ HM132764/ HM132765/ HM132766/ HM132767/ HM132768/ HM132769/ HM132770/ HM132771/ HM132772/ HM132773/ HM132774/ HM132775/ HM132776/ HM132777/ HM132778/ HM132779/ HM132780/ HM132781/ HM132782/ HM132783/ HM132784/ HM132785/ HM132786/ HM132787/ HM132788/ HM132789/ HM132790/ HM132791/ HM132792/ HM132793/ HM132794/ HM132795/ HM132796/ HM132797/ HM132798/ HM132799/ HM132800/ HM132801/ HM132802/ HM132803/ HM132804/ HM132805/ HM132806/ HM132807/ HM132808/ HM132809/ HM132810/ HM132811/ HM132812/ HM132813/ HM132814/ HM132815/ HM132816/ HM132817/ HM132818/ HM132819/ HM132820/ HM132821/ HM132822/ HM132823/ HM132824/ HM132825/ HM132826/ HM132827/ HM132828/ HM132829/ HM132830/ HM132831/ HM132832/ HM132833/ HM132834/ HM132835/ HM132836
  • [Grant] United States / NIAID NIH HHS / AI / AI007051; United States / NIAID NIH HHS / AI / T32 AI007051; United States / NIAID NIH HHS / AI / AI07844; United States / NIAID NIH HHS / AI / AI048115; United States / NIAID NIH HHS / AI / R21 AI078449; United States / NIAID NIH HHS / AI / R01 AI048115
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Complementarity Determining Regions
  • [Other-IDs] NLM/ NIHMS469378; NLM/ PMC3667605
  •  go-up   go-down


7. Jain M, Armstrong RJE, Elneil S, Barker RA: Transplanted Human Neural Precursor Cells Migrate Widely but Show no Lesion-Specific Tropism in the 6-Hydroxydopamine Rat Model of Parkinson's Disease. Cell Transplant; 2006 Aug;15(7):579-593

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplanted Human Neural Precursor Cells Migrate Widely but Show no Lesion-Specific Tropism in the 6-Hydroxydopamine Rat Model of Parkinson's Disease.
  • Parkinson's disease (PD), while primarily associated with degeneration of nigrostriatal dopamine neurons, is now increasingly recognized to have more widespread cell loss and so the most effective cell replacement therapy should target all these neuronal losses.
  • Neural precursor cells might be ideal in this regard as in certain circumstances they have been shown to migrate widely following transplantation into the CNS.
  • The aim of this study was to investigate whether transplanted human expanded neural precursor cells (hENPs) could migrate to sites of established or evolving pathology in the adult brain using the 6-hydroxydopamine (6-OHDA) rat model of PD. hENPs were grafted into the striatum prior to, at the same time as, or after the animals received a 6-OHDA lesion to the medial forebrain bundle.
  • The presence of donor cells was then assessed in a distant site of cell loss (substantia nigra) or sites where cell death would not be expected (frontal cortex and globus pallidus).
  • Donor cells were found distant from the site of implantation but the migration of these hENPs was not significantly greater in the 6-OHDA-lesioned brain and the cells did not specifically target the site of cell loss in the substantia nigra.
  • The temporal relationship of grafting relative to the lesion, and therefore dopaminergic cell death, did not affect the migration of hENPs nor their differentiation.
  • We conclude that while transplanted hENPs are capable of migration away from the site of implantation, they show no specific tropism for sites of ongoing or established nigral dopaminergic cell loss in this lesion model.
  • Therefore, the use of such cells to replace the range of neurons lost in PD is likely to require a deeper understanding of the migratory cues in the damaged adult brain and some manipulation of these cells prior to transplantation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28849971.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cortex / Migration / Neural stem cells / Neural transplantation / Progenitor cells / Substantia nigra
  •  go-up   go-down


8. Jensen CT, Kharazi S, Böiers C, Cheng M, Lübking A, Sitnicka E, Jacobsen SE: FLT3 ligand and not TSLP is the key regulator of IL-7-independent B-1 and B-2 B lymphopoiesis. Blood; 2008 Sep 15;112(6):2297-304
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although IL-7 appears to be the primary cytokine regulator of fetal and adult B lymphopoiesis in mice, considerable fetal B lymphopoiesis and postnatal B cells are sustained in the absence of IL-7; in humans, B-cell generation is suggested to be largely IL-7-independent, as severe combined immune-deficient patients with IL-7 deficiency appear to have normal B-cell numbers.
  • Although thymic stromal lymphopoietin (TSLP) has been proposed to be the main factor driving IL-7-independent B lymphopoiesis and to distinguish fetal from adult B-cell progenitor development in mice, recent studies failed to support a primary role of TSLP in IL-7-independent fetal B-cell development.
  • However, the role of TSLP in IL-7-independent adult B lymphopoiesis and in particular in regulation of B-1 cells remains to be established.
  • Here we demonstrate that, rather than TSLP, IL-7 and FLT3 ligand are combined responsible for all B-cell generation in mice, including recently identified B-1-specified cell progenitors.
  • Thus, the same IL-7- and FLT3 ligand-mediated signal-ing regulates alternative pathways of fetal and adult B-1 and B-2 lymphopoiesis.
  • [MeSH-minor] Animals. Cell Lineage. Fetus / cytology. Mice

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18566323.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501838; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-7; 0 / Membrane Proteins; 0 / flt3 ligand protein; 0 / thymic stromal lymphopoietin
  •  go-up   go-down


9. McClure RF, Remstein ED, Macon WR, Dewald GW, Habermann TM, Hoering A, Kurtin PJ: Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol; 2005 Dec;29(12):1652-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior.
  • Adult, de novo B-cell lymphomas meeting the WHO morphologic criteria for atypical Burkitt/Burkitt-like lymphoma cause diagnostic difficulty for pathologists because the genetic and clinical characteristics of this group of lymphomas have not been clearly defined.
  • Nine childhood Burkitt lymphomas (BL) and 87 adult, de novo diffuse large B-cell lymphomas (DLBL) were similarly evaluated for comparison.
  • We propose that adult B-cell lymphomas with BLL morphology are a phenotypically and genetically heterogeneous group of aggressive lymphomas, biologically distinct from childhood BL.
  • Until biologically accurate subgroups within this morphologically defined group are identified, it is appears that both recognition of BLL morphology and direct evaluation for the presence of MYC fusion to immunoglobulin genes are important for identification of adult patients with poorer prognosis than those with DLBL.
  • [MeSH-major] Burkitt Lymphoma / genetics. Genotype. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / pathology. Phenotype
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Child. Child, Preschool. Diagnosis, Differential. Female. Follow-Up Studies. Histocytochemistry. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-myc / analysis. Survival Analysis

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327438.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


10. Prabhu S, Gottlieb DJ, Varikatt W, St Heaps L, Diaz S, Smith A: Adult B-cell acute lymphoblastic leukemia with two unrelated abnormal cytogenetic clones. Cancer Genet Cytogenet; 2010 Aug;201(1):24-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult B-cell acute lymphoblastic leukemia with two unrelated abnormal cytogenetic clones.
  • The presence of two different abnormal cell lines at diagnosis in hematologic malignancies is rare and raises the question of etiology and pathogenesis--two separate malignant lineages occurring together or a common stem cell malignancy?
  • On the basis of the morphology, flow cytometry, and lack of myeloid-associated markers, a diagnosis of precursor B-cell acute lymphoblastic leukemia (B-ALL) was made.
  • After standard treatment for B-ALL, BM cytogenetic analysis showed disappearance of the dic(7;9) cell line but persistence of cells with trisomy 8.
  • [MeSH-major] Leukemia, B-Cell / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20633764.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Primo D, Tabernero MD, Perez JJ, Rasillo A, Sayagués JM, Espinosa AB, Lopez-Berges MC, García-Sanz R, Gutierrez NC, Hernandez JM, Romero M, Osuna CS, Giralt M, Barbon M, San Miguel JF, Orfao A: Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics. Leukemia; 2005 May;19(5):713-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics.
  • Philadelphia-positive (Ph(+)) B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a genetically heterogeneous disease with a very poor prognosis.
  • In this study, we analyzed the frequency of supernumerary Ph, trisomy 8, monosomy 7, and del(9p21) by FISH and its relationship with the characteristics of the disease, in 46 BCR/ABL(+) adult BCP-ALL patients.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Aberrations. DNA / genetics. Disease-Free Survival. Female. Flow Cytometry / methods. Humans. In Situ Hybridization, Fluorescence / methods. Interphase. Karyotyping. Male. Middle Aged. Ploidies. Time Factors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15789066.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9007-49-2 / DNA; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


12. Bao L, Gross SA, Ryder J, Wang X, Ji M, Chen Y, Yang Y, Zhu S, Irons RD: Adult precursor B lymphoblastic leukemia in Shanghai, China: characterization of phenotype, cytogenetics and outcome for 137 consecutive cases. Int J Hematol; 2009 May;89(4):431-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult precursor B lymphoblastic leukemia in Shanghai, China: characterization of phenotype, cytogenetics and outcome for 137 consecutive cases.
  • Acute lymphoblastic leukemia (ALL) accounts for 20-30% of adult leukemia in the West.
  • However, detailed studies of B-cell-specific ALL in adult Asian populations are lacking.
  • We diagnosed and characterized 137 consecutive cases of precursor B lymphoblastic leukemia (precursor B-cell ALL) presented to our laboratory in Shanghai using the WHO 2001 classification system.
  • In contrast to Western studies, females (71) outnumbered males (66) partly due to an increased prevalence of the CD10- pro B-cell phenotype.
  • Females with a CD10- pro B-cell phenotype exhibited significantly better overall survival than males.
  • Cases of precursor B cell ALL lacking the PH/BCR/ABL genotype exhibited a pronounced age-dependent, gender prevalence with a modal age in the sixth decade for females compared to the second decade for males.
  • These findings suggest significant geographic heterogeneity in precursor B-cell ALL which may be of both etiological and therapeutic significance.
  • [MeSH-major] Chromosome Aberrations. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. China. Female. Humans. Male. Middle Aged. Phenotype. Sex Characteristics. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19322628.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Ma J, Liu YF, Chen SM, Zhang QT, Sun L, Liu LX, Wan DM, Chen SQ, Xie XS, Meng XL, Jiang ZX, Cheng YD, Wang F, Sun H: [Immunophenotyping characteristics of adult patients with acute lymphoblastic leukemia in different ages]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug;18(4):942-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunophenotyping characteristics of adult patients with acute lymphoblastic leukemia in different ages].
  • The purpose of this study was to investigate the immunophenotyping characteristics of adult acute lymphoblastic leukemia (ALL) patients in groups of different ages.
  • The results indicated that (1) all the 82 cases of T-cell acute lymphoblastic leukemia (T-ALL) expressed CD7 (100%) while the positive rate of CD2 remarkably decreased with aging.
  • Moreover, there were significant differences of the myeloid antigen (MyAg) and CD13 expression between the older adults and younger adults (p < 0.05). (2) As to adult B-cell acute lymphoblastic leukemia (B-ALL), the positive rates of CD19 and HLA-DR in 178 cases were 100%; the positive rate of CD33 in young adults was significant higher than that in adolescents (p < 0.05), the differences of the other marker expressions failed to reach statistical significance in adult B-ALL patients.
  • It is concluded that the immunophenotypes of adult T-ALL are evidently heterogeneous in different ages, and expression with more aberrant phenotypes indicates poor prognostic significance in patients older than 35 years.
  • There is no significant association of immunophenotypes with ages among different age groups of adult B-ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20723305.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD19; 0 / Antigens, CD2; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


14. Familiades J, Bousquet M, Lafage-Pochitaloff M, Béné MC, Beldjord K, De Vos J, Dastugue N, Coyaud E, Struski S, Quelen C, Prade-Houdellier N, Dobbelstein S, Cayuela JM, Soulier J, Grardel N, Preudhomme C, Cavé H, Blanchet O, Lhéritier V, Delannoy A, Chalandon Y, Ifrah N, Pigneux A, Brousset P, Macintyre EA, Huguet F, Dombret H, Broccardo C, Delabesse E: PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia; 2009 Nov;23(11):1989-98
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study.
  • Adult and child B-cell progenitor acute lymphoblastic leukemia (BCP-ALL) differ in terms of incidence and prognosis.
  • We report here the most extensive analysis of alterations of PAX5 coding sequence in 117 adult BCP-ALL patients in the unique clinical protocol GRAALL-2003/GRAAPH-2003.
  • Our study demonstrates that PAX5 is mutated in 34% of adult BCP-ALL, mutations being partial or complete deletion, partial or complete amplification, point mutation or fusion gene.
  • PAX5 complete loss seems to be a secondary event and is significantly associated with BCR-ABL1 or TCF3-PBX1 fusion genes and a lower white blood cell count.
  • [MeSH-major] B-Cell-Specific Activator Protein / genetics. Basic Helix-Loop-Helix Transcription Factors / genetics. DNA-Binding Proteins / genetics. Fusion Proteins, bcr-abl / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Benzamides. Clinical Trials, Phase II as Topic. Gene Dosage. Gene Rearrangement, T-Lymphocyte / genetics. Genomics. Haplotypes. Humans. Imatinib Mesylate. Immunoglobulin Heavy Chains / genetics. Immunophenotyping. Middle Aged. Multicenter Studies as Topic. Piperazines / therapeutic use. Point Mutation. Prognosis. Prospective Studies. Pyrimidines / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19587702.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / B-Cell-Specific Activator Protein; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Benzamides; 0 / DNA-Binding Proteins; 0 / Immunoglobulin Heavy Chains; 0 / PAX5 protein, human; 0 / Piperazines; 0 / Proto-Oncogene Proteins; 0 / Pyrimidines; 0 / TCF3 protein, human; 0 / pbx1 protein, human; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


15. Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, Gershenson DM, Brown J: Antiangiogenic therapy for granulosa cell tumors of the ovary. J Clin Oncol; 2009 May 20;27(15_suppl):5574

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiangiogenic therapy for granulosa cell tumors of the ovary.
  • Of these, 7 had adult granulosa cell tumors (GCT) and one had a juvenile GCT.
  • CONCLUSIONS: Anti-VEGF therapy is highly effective in patients with ovarian granulosa cell tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962607.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Olofsson S, Dahl O, Jerkeman M, Cohn-Cedermark G, Klepp O, Stierner U, Törnblom M, Wahlqvist R, Cavallin-Ståhl E, SWENOTECA: Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): A report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA. J Clin Oncol; 2009 May 20;27(15_suppl):5015

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): A report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA.
  • : 5015 Background: From July 1995 to December 2003, 602 adult patients from Sweden and Norway with metastatic testicular NSGCT were included in a population-based multicenter SWENOTECA protocol with strict guidelines for staging, treatment and follow-up.
  • If still unsatisfactory response the treatment was intensified according to step 2 involving high-dose chemotherapy with stem cell rescue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962902.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Vry J, Martínez-Martínez P, Losen M, Bode GH, Temel Y, Steckler T, Steinbusch HW, Baets M, Prickaerts J: Low Current-driven Micro-electroporation Allows Efficient In Vivo Delivery of Nonviral DNA into the Adult Mouse Brain. Mol Ther; 2010 Jun;18(6):1183-1191

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low Current-driven Micro-electroporation Allows Efficient In Vivo Delivery of Nonviral DNA into the Adult Mouse Brain.
  • : Viral gene transfer or transgenic animals are commonly used technologies to alter gene expression in the adult brain, although these approaches lack spatial specificity and are time consuming.
  • We delivered plasmid DNA locally into the brain of adult C57BL/6 mice in vivo by voltage- and current-controlled electroporation.
  • In conclusion, low current-controlled electroporation is an excellent approach for electroporation in the adult brain, i.e., gene function can be influenced locally at a high level with no mortality and minimal tissue damage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178496.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Sengupta N, Caballero S, Sullivan SM, Chang LJ, Afzal A, Li Calzi S, Kielczewski JL, Prabarakan S, Ellis EA, Moldovan L, Moldovan NI, Boulton ME, Grant MB: Regulation of Adult Hematopoietic Stem Cells Fate for Enhanced Tissue-specific Repair. Mol Ther; 2009 Sep;17(9):1594-1604

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of Adult Hematopoietic Stem Cells Fate for Enhanced Tissue-specific Repair.
  • : The ability to control the differentiation of adult hematopoietic stem cells (HSCs) would promote development of new cell-based therapies to treat multiple degenerative diseases.
  • Our data confirm that expression of the cell-specific gene RPE65 promoted fate determination of HSCs toward RPE for targeted tissue repair, and did so in part by activation of adenylate cyclase signaling pathways.
  • Expression by HSCs of single genes unique to a differentiated cell may represent a novel experimental paradigm to influence HSC plasticity, force selective differentiation, and ultimately lead to identification of pharmacological alternatives to viral gene delivery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178547.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Ganesan P, Raina V, Kumar R: A phase II pilot study of valproic acid in relapsed/refractory chronic lymphocytic leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):7081

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II pilot study of valproic acid in relapsed/refractory chronic lymphocytic leukemia.
  • : 7081 Background: Valproic acid (VA) has demonstrated cell-kill by triggering pro-apoptotic pathways in chronic lymphocytic leukemia (CLL) in preclinical studies.
  • METHODS: Adult patients with CLL diagnosed by the NCI-WG criteria who had received at least one previous fludarabine-based therapy and subsequently progressed or relapsed with ECOG performance status (PS) ≤3 and normal organ functions were included.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961474.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Kohman L, Watson D, Herndon J 2nd, Eves N, Haithcock B, Loewen G, Jones L: CALGB 140803-Association between cardiorespiratory fitness and overall survival in operable lung cancer patients: Ancillary analysis of protocol 9238. J Clin Oncol; 2009 May 20;27(15_suppl):7518

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7518 Background: Cardiorespiratory fitness is a well-established independent predictor of all-cause mortality in a broad range of adult populations.
  • We examined the association between cardiorespiratory fitness and all-cause mortality in 398 patients with non-small cell lung cancer (NSCLC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963490.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Udoh FV, Udoh PB: Hepatotoxicity of the Methanol Extract of Carica papaya. (Paw-Paw) Seeds in Wistar Rats. Pharm Biol; 2005;43(4):349-352

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tolerated doses of C. papaya. were estimated in acute toxicity studies and administered orally, single or repeated doses, for 30 days to adult male rats weighing between 190 and 200 g, which were divided into four groups of five rats per group.
  • These biochemical and pathological changes indicated liver cell damage and malfunction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28925838.001).
  • [ISSN] 1744-5116
  • [Journal-full-title] Pharmaceutical biology
  • [ISO-abbreviation] Pharm Biol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Carica papaya / Wistar rats / hepatotoxicity / liver sections
  •  go-up   go-down


22. Pestina TI, Hargrove PW, Jay D, Gray JT, Boyd KM, Persons DA: Correction of Murine Sickle Cell Disease Using γ-Globin Lentiviral Vectors to Mediate High-level Expression of Fetal Hemoglobin. Mol Ther; 2009 Feb;17(2):245-252

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correction of Murine Sickle Cell Disease Using γ-Globin Lentiviral Vectors to Mediate High-level Expression of Fetal Hemoglobin.
  • : Increased levels of red cell fetal hemogloblin, whether due to hereditary persistence of expression or from induction with hydroxyurea therapy, effectively ameliorate sickle cell disease (SCD).
  • Therefore, we developed erythroid-specific, γ-globin lentiviral vectors for hematopoietic stem cell (HSC)-targeted gene therapy with the goal of permanently increasing fetal hemoglobin (HbF) production in sickle red cells.
  • We evaluated two different γ-globin lentiviral vectors for therapeutic efficacy in the BERK sickle cell mouse model.
  • Adult erythroid cells have β-globin mRNA 3'-UTR-binding proteins that enhance β-globin mRNA stability and we postulated this design might enhance γ-globin expression.
  • Stem cell gene transfer was efficient and nearly all red cells in transplanted mice expressed human γ-globin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28192693.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Lonetti A, Iacobucci I, Ferrari A, Messina M, Cilloni D, Soverini S, Papayannidis C, Baccarani M, Foà R, Martinelli G: Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients. J Clin Oncol; 2009 May 20;27(15_suppl):7049

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients.
  • : 7049 Since the activation-induced cytidine deaminase (AID) enzyme can target non-immunoglobulin (Ig) genes and may even act as a genome-wide mutator, we investigated AID expression in BCR-ABL1-positive ALL and in chronic myeloid leukemia (CML) at the time of progression to blast crisis.
  • On the 61 de novo adult BCR-ABL1-positive ALL patients (pts), AID mRNA and protein were detected in 36 (59%); their expression correlated with BCR-ABL1 transcript levels and disappeared after treatment with tyrosine kinase inhibitors at the time of remission.
  • Our findings show that BCR-ABL1-positive ALL cells aberrantly express different isoforms of AID that can act as mutator outside the Ig gene loci in promoting genetic instability in leukemia cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961429.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Pistollato F, Abbadi S, Rampazzo E, Viola G, Della Puppa A, Cavallini L, Panchision DM, Te Kronnie G, Basso G: Glioblastoma-derived cells exhibit differential responses to glycolysis inhibition under hypoxia. J Clin Oncol; 2009 May 20;27(15_suppl):e13031

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our results show that adult GBM displaying a highly immature phenotype manifested the highest resistance to glucose deprivation.
  • Furthermore, increase of multi-drug resistant cell fraction, described as side population, occurred following 2-DG treatment, but only under hypoxia.
  • Also, hypoxia inhibits the mitochondria-controlled apoptosis induced by 2-DG, by conferring cell resistance through progressive activation of pro-survival NF-kB and induction of tumor cell autophagy.
  • These results indicate differences in tumor cells behavior that may be predictive of cell response to therapy aiming to limit glucose uptake or glucose metabolism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962877.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Giles FJ, O'Brien S, Rizzieri DA, Vey N, Krug U, Sekeres M, Jacobsen TF, Nilsson BI, Staudacher K: A phase II study with CP-4055 in patients with second salvage AML. J Clin Oncol; 2009 May 20;27(15_suppl):7047

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7047 Background: CP-4055 (cytarabine 5'-elaidic acid ester) is a novel derivative of cytarabine, independent of nucleoside transporters to enter the cell.
  • The aim of this study was to assess efficacy and safety of CP-4055 when given as second salvage therapy to patients (pts) with acute myeloid leukemia (AML).
  • METHODS: Adult pts who received two previous chemotherapy regimens and who had refractory/relapsed AML (CR after first salvage therapy lasting less than 6 months) were enrolled.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961426.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Bonini A, Tieghi A, Gamberi B, Imovilli A, Carbonelli C, Spaggiari L, Gugliotta L: Caspofungin for invasive aspergillosis: A single-centre prospective study. J Clin Oncol; 2009 May 20;27(15_suppl):e20618

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Caspofungin (Caspo) is the first drug able to inhibit the growth of the fungal cell wall.
  • METHODS: Since 2004 we began a prospective study with the administration of Caspo as first line therapy in 63 consecutive adult neutropenic pts.
  • The diagnoses were: leukemia 44, myeloma 3, lymphoma 16; the disease's phases were: new onset 24, remission 16, relapse 23.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961616.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Cabanillas ME, Waguespack SG, Bronstein Y, Williams M, Feng L, Sherman SI, Busaidy NL: Treatment (tx) with tyrosine kinase inhibitors (TKIs) for patients (pts) with differentiated thyroid cancer (DTC): The M. D. Anderson Cancer Center (MDACC) experience. J Clin Oncol; 2009 May 20;27(15_suppl):6060

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Adult pts with a diagnosis of DTC treated with single agent sorafenib (SOR) or sunitinib (SUN), and who had a baseline and at least 1 follow-up (f/u) scan after 3 months (mos) of therapy, were included.
  • 7 patients had papillary, 6 follicular (including 2 insular subtypes), 2 Hurthle cell.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961926.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Necchi A, Colecchia M, Nicolai N, Mego M, De Giorgi U, Mikuz G, Sava T, Di Nicola M, Pastorino U, Salvioni R: Somatic malignant differentiation in adult male germ-cell tumors (GCTs): Preliminary evidences from the INTera database (International Project for Teratoma with Malignant Transformation). J Clin Oncol; 2009 May 20;27(15_suppl):e16013

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic malignant differentiation in adult male germ-cell tumors (GCTs): Preliminary evidences from the INTera database (International Project for Teratoma with Malignant Transformation).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962924.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Mohty M, Balere M, Socie G, Milpied N, Ifrah N, Harousseau JL, Michallet M, Blaise D, Esperou H, Yakoub-Agha I, SFGM-TC: Effect of antithymocyte globulins (ATG) as part of the myeloablative conditioning (MAC) regimen on the risk of severe graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (allo-SCT) from matched-unrelated donors (MUD). J Clin Oncol; 2009 May 20;27(15_suppl):7025

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of antithymocyte globulins (ATG) as part of the myeloablative conditioning (MAC) regimen on the risk of severe graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (allo-SCT) from matched-unrelated donors (MUD).
  • The purpose of the study was to compare the incidence and severity of acute and chronic GVHD as well as overall outcome.
  • 171 adult patients with acute leukemia and MDS, for whom detailed allelic HLA typing (4 digits) was available, were included.
  • With a median follow-up of 30.3 (range, 2.6-68.1) months, grade 0-1 and 2-4 acute GVHD occurred in 74 (46%) and 88 patients (54%) respectively, with grade 3-4 acute GVHD being significantly lower in the ATG group (18% vs. 32%; p = 0.04).
  • In multivariate analysis, an HLA allelic mismatch and the non-use of ATG were associated with an increased risk of grade 3-4 acute GVHD (RR = 2.80, 95% CI, 1.5-5.3, p = 0.001; and RR = 2.4, 95% CI, 1.1-5.0, p = 0.02 respectively).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961398.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Bukhari MH, Byron E, Strosberg JR, Nasir NA, Henderson-Jackson E, Bui M, Hakam A, Domenico C, Kvols L, Nasir A: Primary gastroenteropancreatic poorly differentiated neuroendocrine carcinoma: Clinico-pathologic analysis of 68 cases. J Clin Oncol; 2009 May 20;27(15_suppl):e15616

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Under an IRB-approved protocol, clinico-pathologic data were collected on 68 adult patients with GEP-PDNECA who had undergone biopsy / resection at MCC or outside institution.
  • Of 68 tumors 37 (54%) were classified as small cell carcinoma (SCCA), 16 (24%) large cell carcinoma (LCCA), 5 (7%) mixed small and large cell (MSLCCA) and 10 (15%) poorly differentiated carcinoma with neuroendocrine features (PDCA-NEF).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962728.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Cunningham SC, Spinoulas A, Carpenter KH, Wilcken B, Kuchel PW, Alexander IE: AAV2/8-mediated Correction of OTC Deficiency Is Robust in Adult but Not Neonatal Spf&lt;sup&gt;ash&lt;/sup&gt; Mice. Mol Ther; 2009 Aug;17(8):1340-1346

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AAV2/8-mediated Correction of OTC Deficiency Is Robust in Adult but Not Neonatal Spf<sup>ash</sup> Mice.
  • In this study, we investigated metabolic correction in neonatal and adult male OTC-deficient Spf<sup>ash</sup> mice following adeno-associated virus (AAV)2/8-mediated delivery of the murine OTC complementary DNA under the transcriptional control of a liver-specific promoter.
  • Substantially supraphysiological levels of OTC enzymatic activity were readily achieved in both adult and neonatal mice following a single intraperitoneal (i.p.) injection, with metabolic correction in adults being robust and life-long.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28160908.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Virgo KS, Fedewa SA, Chen AY, Stewart AK, Flanders WD, Ward EM: Hospital characteristics associated with surgery for non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):6543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hospital characteristics associated with surgery for non-small cell lung cancer.
  • : 6543 Background: Previous research suggests that black patients are less likely to undergo curative-intent surgery for early stage non-small cell lung cancer (NSCLC) compared to whites, holding all else constant.
  • METHODS: All adult patients ages 19-104 diagnosed with an invasive initial primary early stage (TNM I-II) NSCLC during 2003-2005 were selected from the National Cancer Data Base (NCDB).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964059.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Barbera LC, Krzyzanowska M, Elit L, Saskin R, Bierman A: Differences in uptake of postoperative adjuvant chemotherapy for lung cancer: Results from the Project for an Ontario Women's Health Evidence-Based Report Card (POWER) study. J Clin Oncol; 2009 May 20;27(15_suppl):6556

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Results pertaining to the uptake of postoperative adjuvant chemotherapy for non-small cell lung cancer (NSCLC) are presented.
  • All adult patients who underwent resection of NSCLC between April 2003 and May 2004 were included in the cohort.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963771.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Kesserwan C, Sokolic R, Cowen E, Garabedian E, Pittaluga S, Baird K, López-Terrada D, Issekutz A, Bridge J, Wayne A, Candotti F: Dermatofibrosarcoma protuberans (DFSP) in six patients with ADA-SCID. J Clin Oncol; 2009 May 20;27(15_suppl):10570

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All lesions showed a spindle cell proliferation of the dermis, extending into the subcutaneous fat.
  • A storiform pattern was only noticed in one adult patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963775.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Iacobucci I, Storlazzi C, Lonetti A, Ferrari A, Messina M, Cilloni D, Papayannidis C, Baccarani M, Foà R, Martinelli G: IKZF1 (IKAROS) deletions as a prognostic marker in BCR-ABL1 positive acute lymphoblastic leukemia patients: A GIMEMA ALL WP Report. J Clin Oncol; 2009 May 20;27(15_suppl):11005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IKZF1 (IKAROS) deletions as a prognostic marker in BCR-ABL1 positive acute lymphoblastic leukemia patients: A GIMEMA ALL WP Report.
  • : 11005 Expression of BCR-ABL1 in hematopoietic stem cells can alone induce a chronic myeloid leukemia (CML) but cooperating oncogenic lesions are required for the generation of a blastic leukemia.
  • To identify oncogenic sub-microscopic lesions that cooperate with BCR-ABL1 to induce ALL, by high resolution single nucleotide polymorphism (SNP) arrays (250K NspI and SNP 6.0, Affymetrix) we studied 106 patients (pts) with de novo adult BCR-ABL1-positive ALL.
  • Gene expression profiling analysis of pts with IKZF1 deletion vs wild-type pts identified a unique signature characterized by a down-regulation of genes involved in pre-B-cell differentiation (e.g.
  • VPREB1, VPREB3, IGLL3, BLK), demonstrating that genomic IKZF1 alterations have a strong impact on trascriptoma and contribute to an impaired B-cell differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964054.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Grinshpun A, Condiotti R, N Waddington S, Peer M, Zeig E, Peretz S, Simerzin A, Chou J, Pann CJ, Giladi H, Galun E: Neonatal Gene Therapy of Glycogen Storage Disease Type Ia Using a Feline Immunodeficiency Virus-based Vector. Mol Ther; 2010 Sep;18(9):1592-1598

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previously, we have shown that these vectors are capable of integrating stably into hepatocyte cell lines and adult murine livers and lead to long-term transgene expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178467.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Sudol KL, Mastrangelo MA, Narrow WC, Frazer ME, Levites YR, Golde TE, Federoff HJ, Bowers WJ: Generating Differentially Targeted Amyloid-β Specific Intrabodies as a Passive Vaccination Strategy for Alzheimer's Disease. Mol Ther; 2009 Dec;17(12):2031-2040

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The intrabodies, one with an endoplasmic reticulum (ER) targeting signal and one devoid of a targeting sequence, were assessed in cells harboring a doxycycline (Dox)-regulated mutant human amyloid precursor protein Swedish mutant (hAPP<sup>swe</sup>) transcription unit for their abilities to prevent Aβ peptide egress.
  • Adeno-associated virus (AAV) vectors expressing the engineered intrabodies were administered to young adult 3xTg-AD mice, a model that develops amyloid and Tau pathologies, prior to the initial appearance of intraneuronal Aβ.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178451.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Li H, Lu Y, Witek RP, Chang LJ, Campbell-Thompson M, Jorgensen M, Petersen B, Song S: Ex Vivo Transduction and Transplantation of Bone Marrow Cells for Liver Gene Delivery of α1-Antitrypsin. Mol Ther; 2010 Aug;18(8):1553-1558

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Adult stem cell-based gene therapy holds several unique advantages including avoidance of germline or other undesirable cell transductions.
  • However, this cell source cannot be used in humans for autologous transplantation.
  • In the present study, we tested the feasibility of bone marrow (BM) cell-based liver gene delivery of hAAT.
  • These results demonstrated that rAAV vector-mediated BM cell-based liver gene therapy is feasible for the treatment of AAT deficiency and implies a novel therapy for the treatment of liver diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178512.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Dodiya HB, Bjorklund T, Stansell Iii J, Mandel RJ, Kirik D, Kordower JH: Differential Transduction Following Basal Ganglia Administration of Distinct Pseudotyped AAV Capsid Serotypes in Nonhuman Primates. Mol Ther; 2010 Mar;18(3):579-587

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six intact young adult cynomolgus monkeys received a single 10 µl injection of AAV2/1-GFP, AAV2/5-GFP, or AAV2/8-GFP pseudotyped vectors into the caudate nucleus and putamen bilaterally in a pattern that resulted in each capsid serotype being injected into at least four striatal sites.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28182881.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Metcalf JA, Ma X, Linders B, Wu S, Schambach A, Ohlemiller KK, Kovacs A, Bigg M, He L, Tollefsen DM, Ponder KP: A Self-inactivating γ-Retroviral Vector Reduces Manifestations of Mucopolysaccharidosis I in Mice. Mol Ther; 2010 Feb;18(2):334-342

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This report demonstrates that intravenous (i.v.) injection of a SIN γ-RV expressing canine IDUA from the liver-specific human α<sub>1</sub>-antitrypsin promoter into adult or newborn MPS I mice completely prevents biochemical abnormalities in several organs, and improved bone disease, vision, hearing, and aorta to a similar extent as was seen with administration of the LTR-intact vector to adults.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28182939.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Slováček L, Slováčková B, Jebavý L, Pavlík V: Quality of Life in Adult Patients Treated with Peripheral Blood Progenitor Cell Transplantation: the Effect of Selected Psychosocial, Demographics and Health Aspects on Quality of Life: a Retrospective Analysis. Acta Medica (Hradec Kralove); 2007;50(2):119-124

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of Life in Adult Patients Treated with Peripheral Blood Progenitor Cell Transplantation: the Effect of Selected Psychosocial, Demographics and Health Aspects on Quality of Life: a Retrospective Analysis.
  • AIM: this retrospective study analyses the effect of selected psychosocial, demographics and health aspects on quality of life (QoL) in adult patients treated with peripheral blood progenitor cell transplantation (PBPCT).
  • The QoL in adult patients treated with PBPCT declines with increasing age and with the increasing number of associated diseases.
  • CONCLUSION: The global QoL in an adult patients treated with PBPCT is on a good level.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28949911.001).
  • [ISSN] 1211-4286
  • [Journal-full-title] Acta medica (Hradec Kralove)
  • [ISO-abbreviation] Acta Medica (Hradec Kralove)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  • [Keywords] NOTNLM ; Cell transplantation / Peripheral blood progenitor / Quality of life / Quality of life questionnaires
  •  go-up   go-down


42. Rousková L, Hruška I, Filip S: Issues and Ethical Problems of Stem Cell Therapy - Where is Hippocrates? Acta Medica (Hradec Kralove); 2008;51(2):121-126

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Issues and Ethical Problems of Stem Cell Therapy - Where is Hippocrates?
  • Our paper indicates some ways of the search in forming ethical principles of the stem-cell therapy from the view of biologists and physicians.
  • In this paper important ethical problems are pointed out in order to find answers to some key problems connected with cell therapy and the use of stem cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28550841.001).
  • [ISSN] 1211-4286
  • [Journal-full-title] Acta medica (Hradec Kralove)
  • [ISO-abbreviation] Acta Medica (Hradec Kralove)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  • [Keywords] NOTNLM ; Adult stem cells / Cloning / Embryo / Ethical issue / Stem cell therapy / Stem cells
  •  go-up   go-down


43. Zuo Z, Jones DM, Thomas DA, O'Brien S, Ravandi F, Kantarjian HM, Medeiros LJ, Luthra R, Chen SS: A nine-gene predictor of therapy response in adult Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). J Clin Oncol; 2009 May 20;27(15_suppl):7014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A nine-gene predictor of therapy response in adult Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
  • Expression of the selected genes was assessed using Applied Biosystems low density reverse transcription quantitative PCR (RT-qPCR) arrays in bone marrow (BM) samples from 27 adult Ph+ ALL patients treated with standard chemotherapy plus a tyrosine kinase inhibitor.
  • There was no statistical difference in age, initial peripheral blood white cell and BM blast counts, and initial normalized BCR/ABL1 levels between groups.
  • CONCLUSIONS: Using data-trimming of whole genome expression studies, we defined and validated a nine-gene signature that is an independent predictive marker for therapy response in adult Ph+ ALL patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961387.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Sindt A, Deau B, Brahim W, Staal A, Visanica S, Villarese P, Rault JP, Macintyre E, Delabesse E: Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9. Genes Chromosomes Cancer; 2006 Jun;45(6):575-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9.
  • The t(9;22)(q34;q11) translocation occurs in chronic myeloid leukemia (CML) and adult B-cell acute lymphoblastic leukemia (ALL), leading to fusion of BCR to ABL1 and constitutive activation of ABL1 tyrosine kinase activity.
  • The latter is found in almost all cases of CML and in one third of the cases of t(9;22)-positive adult B-ALL.
  • P190 BCR-ABL1 is found in the remaining two thirds of t(9;22)-positive adult B-ALL cases but only exceptionally in CML.
  • We describe here the first case of t(9;22)(q34;q11) associated with t(10;11)(p13;q14) in acute monocytic leukemia.
  • The recurrent t(10;11)(p13;q14) translocation, usually found in acute myeloid leukemia (AML) and T-ALL, merges PICALM to MLLT10.
  • RT-PCR enabled identification of PICALM-MLLT10 and BCR-ABL1 e1-a2 fusion transcripts; in the context of chronic and acute myeloid leukemia, the latter usually has a monocytic presentation.
  • We also identified overexpression of HOXA9, a gene essential to myeloid differentiation that is expressed in PICALM-MLLT10 and MLL-rearranged acute leukemias.
  • [MeSH-major] Fusion Proteins, bcr-abl / metabolism. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / metabolism. Leukemia, Monocytic, Acute / genetics. Oncogene Proteins, Fusion / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16518848.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / MLLT10 protein, human; 0 / Monomeric Clathrin Assembly Proteins; 0 / Oncogene Proteins, Fusion; 0 / PICALM protein, human; 0 / PICALM-MLLT10 fusion protein, human; 0 / Transcription Factors; 0 / homeobox protein HOXA9; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


45. Wandroo F, Bell A, Darbyshire P, Pratt G, Stankovic T, Gordon J, Lawson S, Moss P: ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia. Int J Lab Hematol; 2008 Apr;30(2):149-57
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia.
  • ZAP-70 is, however, expressed in adult B cell chronic lymphocytic leukemia where it correlates with a poor prognosis.
  • We wished to determine if ZAP-70 is also expressed in pediatric B cell malignancy.
  • A quantitative PCR assay for ZAP-70 expression was established and ZAP-70 expression in a range of human B cell lines was compared with expression in the Jurkat T cell line.
  • ZAP-70 expression was then determined in bone marrow lymphoblasts obtained from 12 patients with pre-B cell acute lymphoblastic leukemia (ALL).
  • ZAP-70 expression was not detected in mature B cell lines but was detected in pre-B cell lines at a level comparable to that seen in T cells.
  • ZAP-70 expression was strongly expressed in nine of the 12 cases of primary pre-B cell lymphoblastic leukemia.
  • The T cell-associated protein kinase ZAP-70 is highly expressed in pre-B lineage cells and most cases of pre-B acute lymphoblastic leukemia.
  • ZAP-70 expression may hold prognostic value for pre-B ALL and raises the prospect of a novel therapeutic target.
  • [MeSH-major] B-Lymphocytes / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cells, B-Lymphoid / metabolism. ZAP-70 Protein-Tyrosine Kinase / metabolism
  • [MeSH-minor] Adolescent. Blotting, Western. Bone Marrow Cells / metabolism. Cell Line, Transformed. Cell Line, Tumor. Child. Child, Preschool. Female. Flow Cytometry. Gene Expression. Humans. Jurkat Cells. Male. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18333847.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


46. Lv L, Wu C, Sun H, Zhu S, Yang Y, Chen X, Fu H, Bao L: Combined 677CC/1298AC genotypes of methylenetetrahydrofolate reductase (MTHFR ) reduce susceptibility to precursor B lymphoblastic leukemia in a Chinese population. Eur J Haematol; 2010 Jun;84(6):506-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined 677CC/1298AC genotypes of methylenetetrahydrofolate reductase (MTHFR ) reduce susceptibility to precursor B lymphoblastic leukemia in a Chinese population.
  • It has been suggested that two MTHFR polymorphisms, 677C>T and 1298A>C, influence risk of acute lymphoblastic leukemia (ALL).
  • Here, we report a case-control study of 127 Chinese patients with adult precursor B lymphoblastic leukemia (B-ALL) to examine correlation between the MTHFR polymorphisms and B-ALL susceptibility in adults.
  • The prevalence for joint MTHFR genotypes 677CC/1298AC was significantly lower in the female B-ALL cases than in the controls [odds ratio (OR) = 0.06, 95% CI = 0.00-0.53, P = 0.0033] and no differences among the men [OR = 0.71, 95% CI = 0.20-2.53, P = 0.55], suggesting that protective effects of combined MTHFR 677CC/1298AC genotypes on susceptibility of adult B-ALL are gender bias toward women with 677CC/1298AC women being at a 17-fold reduced odds to develop B-ALL.
  • [MeSH-major] Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Single Nucleotide. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Aged. Asian Continental Ancestry Group / genetics. Base Sequence. Case-Control Studies. China. Confidence Intervals. DNA Primers / genetics. Female. Gene Frequency. Genetic Predisposition to Disease. Genotype. Haplotypes. Humans. Male. Middle Aged. Odds Ratio. Sex Characteristics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20374270.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


47. Li Q, Chen Z, You Y, Zou P: Transient pancytopenia preceding acute lymphoblastic leukemia with positive Philadelphia chromosome. Leuk Res; 2008 Aug;32(8):1317-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient pancytopenia preceding acute lymphoblastic leukemia with positive Philadelphia chromosome.
  • Transient pancytopenia preceding acute lymphoblastic leukemia (pre-ALL) is a rare but well-known occurrence usually affecting children and adolescents.
  • To the best of our knowledge, this is the first report of adult B-cell type pre-ALL with positive Philadelphia chromosome and P190(BCR-ABL) published in the literature.
  • We report the case of a 49-year-old woman who was diagnosed with B-cell type ALL associated positive Philadelphia chromosome and P190(BCR-ABL) preceded by transient pancytopenia.
  • [MeSH-minor] Female. Fusion Proteins, bcr-abl / analysis. Humans. Immunophenotyping. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Preleukemia / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18291524.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


48. Richl P, Stern U, Lipsky PE, Girschick HJ: The lambda gene immunoglobulin repertoire of human neonatal B cells. Mol Immunol; 2008 Jan;45(2):320-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, we analyzed and compared the lambda chain immunoglobulin repertoire of individual IgD+ human neonatal B cells with the adult peripheral B cell VlambdaJlambda repertoire.
  • The adult B cell repertoire revealed nearly the same predominance of genes in the non-productive and productive repertoire.
  • Insertions of non-templated nucleotides at the VlambdaJlambda-junction by the enzyme TdT were less frequent as compared to the adult, but the CDR3 length was the same.
  • These data provide evidence that the primary usage and subsequent selection of Vlambda genes in the neonate are surprisingly comparable with the adult.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17675156.001).
  • [ISSN] 0161-5890
  • [Journal-full-title] Molecular immunology
  • [ISO-abbreviation] Mol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / Complementarity Determining Regions; 0 / Immunoglobulin D; 0 / Immunoglobulin J-Chains; 0 / Immunoglobulin lambda-Chains; EC 2.7.7.31 / DNA Nucleotidylexotransferase; EC 3.1.- / Exonucleases
  •  go-up   go-down


49. Song JH, Schnittke N, Zaat A, Walsh CS, Miller CW: FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias. Leuk Res; 2008 Nov;32(11):1751-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias.
  • Engineered FBXW7 null cells display cell cycle and chromosome stability defects.
  • Mutations of FBXW7 have been found in human colorectal, ovarian, endometrial tumors and T-cell acute lymphocytic leukemias.
  • Prompted by these findings we have examined acute myeloid leukemia, non-Hodgkin's lymphoma, T-cell acute lymphocytic leukemia, B-cell acute lymphocytic leukemia and adult T-cell leukemia DNA for mutations of the FBXW7 gene.
  • As expected, mutations were found in T-cell acute lymphocytic leukemias.
  • However mutations of FBXW7 were also found in four of 118 B-cell acute lymphocytic leukemias and one of 24 adult T-cell leukemia samples.
  • These observations suggest that disruption of FBXW7 has a role in several forms of lymphocytic leukemias and not exclusively T-cell acute lymphocytic leukemia.
  • [MeSH-major] Burkitt Lymphoma / genetics. Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, Non-Hodgkin / genetics. Mutation / genetics. Ubiquitin-Protein Ligases / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18485478.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


50. Miller AL, Komak S, Webb MS, Leiter EH, Thompson EB: Gene expression profiling of leukemic cells and primary thymocytes predicts a signature for apoptotic sensitivity to glucocorticoids. Cancer Cell Int; 2007 Nov 28;7:18
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pediatric CD4+/CD8+ T-cell leukemia was represented by 3 CEM clones: two sensitive, CEM-C7-14 and CEM-C1-6, and one resistant, CEM-C1-15, to Dex.
  • GC-sensitive pediatric B-cell leukemia was represented by the SUP-B15 line and adult B-cell leukemia by RS4;11 cells.
  • Kasumi-1 cells gave an example of the rare Dex-sensitive acute myeloblastic leukemia (AML).
  • To test the generality of the correlations in malignant cell gene sets, we compared with GC effects on mouse non-transformed thymocytes.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Growth Differ. 1995 May;6(5):505-13 [7647033.001]
  • [Cites] Leuk Res. 1997 Jan;21(1):45-50 [9029185.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3684-93 [9721879.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2730-41 [9763557.001]
  • [Cites] Int Immunol. 1998 Dec;10(12):1807-17 [9885901.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1209-17 [10438708.001]
  • [Cites] Science. 1999 Nov 26;286(5445):1735-8 [10576740.001]
  • [Cites] Cell Death Differ. 1999 Dec;6(12):1182-9 [10637434.001]
  • [Cites] Hum Mol Genet. 2000 Jul 1;9(11):1681-90 [10861295.001]
  • [Cites] Oncogene. 2001 Jul 19;20(32):4324-36 [11466613.001]
  • [Cites] Oncogene. 2002 Feb 21;21(9):1346-58 [11857078.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(7):2283-93 [11884613.001]
  • [Cites] Neoplasia. 2002 Jan-Feb;4(1):68-81 [11922393.001]
  • [Cites] Biochem Biophys Res Commun. 2002 May 17;293(4):1254-61 [12054511.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):277-84 [12519866.001]
  • [Cites] Leukemia. 2003 Jan;17(1):17-25 [12529655.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23861-7 [12676946.001]
  • [Cites] J Biol Chem. 2003 Jul 18;278(29):27053-8 [12736248.001]
  • [Cites] Genomics. 2003 Jun;81(6):543-55 [12782123.001]
  • [Cites] Recent Prog Horm Res. 2003;58:175-97 [12795419.001]
  • [Cites] Cancer. 1965 Apr;18:522-9 [14278051.001]
  • [Cites] Eur J Endocrinol. 2004 Jan;150(1):41-7 [14713278.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):20858-65 [14996839.001]
  • [Cites] Mol Cell Endocrinol. 2004 Apr 15;218(1-2):49-55 [15130510.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55809-17 [15509554.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2519-26 [15572593.001]
  • [Cites] Ann Acad Med Singapore. 2004 Sep;33(5 Suppl):S21-2 [15651190.001]
  • [Cites] Mol Endocrinol. 2005 Jun;19(6):1569-83 [15817653.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):6050-6 [16115950.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4131-8 [16118324.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3B):2253-8 [16158972.001]
  • [Cites] Blood. 2006 Mar 1;107(5):2061-9 [16293608.001]
  • [Cites] Oncogene. 2006 Mar 23;25(13):1903-13 [16301999.001]
  • [Cites] Leukemia. 2006 Jun;20(6):987-93 [16598301.001]
  • [Cites] FEBS Lett. 2006 Jun 12;580(14):3539-44 [16730715.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Nov;319(2):887-97 [16914556.001]
  • [Cites] J Dermatol. 2006 Oct;33(10):662-9 [17040494.001]
  • [Cites] J Biol Chem. 2006 Dec 22;281(51):39051-61 [17062574.001]
  • [Cites] Leukemia. 2007 Feb;21(2):281-7 [17151701.001]
  • [Cites] Blood. 2007 May 1;109(9):3929-35 [17218380.001]
  • [Cites] Ann Rheum Dis. 2007 Oct;66(10):1289-95 [17267514.001]
  • [Cites] Cancer Cell Int. 2007;7:3 [17391526.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4482-90 [17483364.001]
  • [Cites] Steroids. 2007 Sep;72(9-10):673-81 [17606285.001]
  • [Cites] Blood. 1991 May 1;77(9):2031-6 [2018839.001]
  • [Cites] J Steroid Biochem Mol Biol. 1991 May;38(5):561-8 [2039752.001]
  • [Cites] Cancer Res. 1988 May 15;48(10):2876-9 [3162827.001]
  • [Cites] Blood. 1985 Jan;65(1):21-31 [3917311.001]
  • [Cites] Int J Cancer. 1985 Aug 15;36(2):241-6 [3926660.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1771-8 [7564524.001]
  • (PMID = 18045478.001).
  • [ISSN] 1475-2867
  • [Journal-full-title] Cancer cell international
  • [ISO-abbreviation] Cancer Cell Int.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA041407
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2228275
  •  go-up   go-down


51. Dorshkind K, Montecino-Rodriguez E: Fetal B-cell lymphopoiesis and the emergence of B-1-cell potential. Nat Rev Immunol; 2007 Mar;7(3):213-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fetal B-cell lymphopoiesis and the emergence of B-1-cell potential.
  • Most B cells in peripheral lymphoid tissues are produced in adult bone marrow and are referred to as B-2 cells.
  • A minor B-cell population, known as the B-1-cell population, that is mainly involved in innate immune responses has been identified in mice.
  • In contrast to B-2 cells, B-1-cell progenitors are produced most efficiently during fetal life.
  • This Review focuses on the emergence of B-1-cell potential during embryogenesis, summarizes recent advances in the delineation of a fetal B-1-cell-specified progenitor, and discusses the possibility that distinct fetal and adult B-cell developmental programmes might be operative in humans.
  • [MeSH-major] B-Lymphocyte Subsets / cytology. Cell Lineage / immunology. Embryonic Stem Cells / cytology. Fetus / cytology. Fetus / immunology. Lymphopoiesis / immunology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318232.001).
  • [ISSN] 1474-1733
  • [Journal-full-title] Nature reviews. Immunology
  • [ISO-abbreviation] Nat. Rev. Immunol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R37 AI021256
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Number-of-references] 107
  •  go-up   go-down


52. Schneider T, Molnár Z, Deák B, Várady E, Tóth E, Csomor J, Matolcsy A, Lovey J, Lengyel Z, Petri K, Gaudi I, Rosta A: [Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma]. Orv Hetil; 2009 Nov 1;150(44):2019-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma].
  • Treatment with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has been considered as the standard therapy for diffuse large B-cell lymphoma (DLBCL) for more than 20 years.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunologic Factors / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Patient Selection. Prednisone / administration & dosage. Rituximab. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861288.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


53. Trost O, Charon-Barra C, Soichot P, Moreau G, Trouilloud P, Malka G: [Isolated mandibular B-cell lymphoma revealed by inferior alveolar nerve anesthesia]. Rev Stomatol Chir Maxillofac; 2009 Apr;110(2):101-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Isolated mandibular B-cell lymphoma revealed by inferior alveolar nerve anesthesia].
  • The biopsy revealed a B-cell lymphoma.
  • In almost all the cases, they present as B-cell tumours of the DLBCL subtype in the WHO classification.
  • [MeSH-major] Hypesthesia / diagnosis. Lymphoma, B-Cell / diagnosis. Mandibular Neoplasms / diagnosis. Mandibular Nerve / physiopathology
  • [MeSH-minor] Adult. Cranial Nerve Diseases / diagnosis. Diagnosis, Differential. Electrodiagnosis. Facial Pain / diagnosis. Follow-Up Studies. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19193387.001).
  • [ISSN] 1776-257X
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


54. Asimakopoulos F, Varmus HE: Cell-specific transduction of Prdm1-expressing lineages mediated by a receptor for avian leukosis virus subgroup B. J Virol; 2009 May;83(10):4835-43
SciCrunch. OMIA - Online Mendelian Inheritance in Animals: Data: Gene Expression .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-specific transduction of Prdm1-expressing lineages mediated by a receptor for avian leukosis virus subgroup B.
  • The transcription factor Blimp-1 has emerged as a regulator of cell fate in embryonic (germ cell) and adult (B- and T-cell immune effector and epithelial) lineages.
  • It has also been proposed to act as a tumor suppressor in B-cell malignancy.
  • Second, it represents the first ALV-based system that allows gene transfer and expression into in vivo-activated mature lymphocytes, a cell type that has traditionally presented formidable challenges to efficient retroviral transduction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Gene Ther. 2003 Feb 10;14(3):263-76 [12639306.001]
  • [Cites] Genome Res. 2002 Dec;12(12):1992-8 [12466304.001]
  • [Cites] Immunity. 2003 Oct;19(4):607-20 [14563324.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3127-38 [14681205.001]
  • [Cites] Folia Biol (Praha). 2004;50(3-4):107-19 [15373344.001]
  • [Cites] J Exp Med. 2004 Oct 18;200(8):967-77 [15492122.001]
  • [Cites] Eur J Immunol. 1992 Jan;22(1):261-6 [1730253.001]
  • [Cites] J Virol. 1993 Apr;67(4):1811-6 [8383211.001]
  • [Cites] Cell. 1993 Sep 24;74(6):1043-51 [8402880.001]
  • [Cites] Cell. 1994 Apr 22;77(2):297-306 [8168136.001]
  • [Cites] Cell. 1994 Jul 15;78(1):9 [8033216.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11241-5 [7972042.001]
  • [Cites] Science. 1997 Apr 25;276(5312):596-9 [9110979.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1218-23 [9448312.001]
  • [Cites] J Virol. 1998 Apr;72(4):3501-3 [9525691.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3675-85 [9851974.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5253-60 [10498877.001]
  • [Cites] J Pathol. 2005 May;206(1):76-86 [15772984.001]
  • [Cites] Nature. 2005 Jul 14;436(7048):207-13 [15937476.001]
  • [Cites] J Exp Med. 2005 Dec 5;202(11):1471-6 [16314438.001]
  • [Cites] J Exp Med. 2006 Feb 20;203(2):311-7 [16492805.001]
  • [Cites] Nat Immunol. 2006 May;7(5):466-74 [16565720.001]
  • [Cites] Nat Immunol. 2006 May;7(5):457-65 [16565721.001]
  • [Cites] Nat Immunol. 2006 May;7(5):445-6 [16622430.001]
  • [Cites] Blood. 2006 May 15;107(10):4090-100 [16424392.001]
  • [Cites] Cell. 2006 Aug 11;126(3):597-609 [16901790.001]
  • [Cites] J Immunol Methods. 2006 Jul 31;314(1-2):80-9 [16842814.001]
  • [Cites] J Exp Med. 2006 Oct 2;203(10):2305-14 [16954370.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17396-401 [17090666.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):936-40 [17237761.001]
  • [Cites] Adv Exp Med Biol. 2007;596:9-30 [17338172.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):14988-93 [17846422.001]
  • [Cites] PLoS Biol. 2007 Oct 16;5(10):e276 [17941720.001]
  • [Cites] Adv Immunol. 2007;96:103-39 [17981205.001]
  • [Cites] J Clin Immunol. 2008 Mar;28(2):97-106 [18071884.001]
  • [Cites] Annu Rev Immunol. 2008;26:133-69 [18370921.001]
  • [Cites] Curr Opin Immunol. 2008 Jun;20(3):259-64 [18554885.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10137-42 [18621715.001]
  • [Cites] J Virol. 2000 Apr;74(8):3572-78 [10729132.001]
  • [Cites] J Immunol. 2000 Nov 15;165(10):5462-71 [11067898.001]
  • [Cites] J Virol. 2000 Dec;74(24):11490-4 [11090145.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S2-9 [11684435.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(13):4771-80 [12052884.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):53-62 [12086888.001]
  • [Cites] Immunity. 2002 Jul;17(1):51-62 [12150891.001]
  • [Cites] Mamm Genome. 2002 Oct;13(10):543-7 [12420130.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8764-9 [12857957.001]
  • (PMID = 19279099.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA105492; United States / NCI NIH HHS / CA / U01CA105492
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Luminescent Proteins; 0 / Prdm1 protein, mouse; 0 / Receptors, Virus; 0 / Transcription Factors; 0 / red fluorescent protein
  • [Other-IDs] NLM/ PMC2682090
  •  go-up   go-down


55. Andriamparany J, Margery J, Grand B, Saint-Blancard P: [Primary mediastinal large B-cell lymphoma: histopathologic features. A specific tumour]. Rev Pneumol Clin; 2010 Jun;66(3):191-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary mediastinal large B-cell lymphoma: histopathologic features. A specific tumour].
  • The diffuse large B-cell lymphomas of the mediastinum were long considered to be a variant of the classic forms of large B-cell lymphomas.
  • However, their clinical and radiological features and especially their histopathological variants point to other lymphoid tumours such as Hodgkin's disease or anaplastic lymphomas, thymic tumours, germ cell tumours or metastatic tumors.
  • Currently, they represent a distinct entity among the large B-cell lymphomas, due to their clinical, pathological and molecular features as well as the outcome.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Mediastinal Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20561485.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


56. Nardi NB: All the adult stem cells, where do they all come from? An external source for organ-specific stem cell pools. Med Hypotheses; 2005;64(4):811-7
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] All the adult stem cells, where do they all come from? An external source for organ-specific stem cell pools.
  • Whereas the "stemness" of embryonic stem cells is not discussed, the primitiveness of a stem cell type within adult organisms is not well determined.
  • Data presently available are either inconclusive or controversial regarding two main topics: maintenance or senescente of the adult stem cell pool; and pluripotentiality of the cells.
  • While programmed senescence or apoptosis following uncorrected mutations represent no problem for mature cells, the maintenance of the stem cell pool itself must be assured.
  • These observations include: organ-specific stem cells are senescent; adult stem cells circulate in the organism; stem cell niches are essential for the existence and function of stem cells; adult stem cells can present lineage markers; embryo-like, pluripotent stem cells are present in adult organisms, as shown by the development of teratomas, tumors composed of derivatives of the three germ layers; and the fact that the gonads may be a reservoir of embryo-like, pluripotent stem cells in adult organisms.
  • The second mechanism for the maintenance of adult stem cells compartments implies a source external to the organ they belong, consisting of pluripotent, embryo-like cells of unrestricted life span, presenting efficient mechanisms for avoiding or correcting mutations and capable to circulate in the organism.
  • According to this model, primitive stem cells exist in a specific organ in adult organisms.
  • They undergo asymmetrical divisions, which originate one "true" stem cell and another one which enters the pool of adult stem cells, circulating through the entire organism.
  • Upon signals liberated by organ-specific niches, this cell becomes activated to express lineage-specific genes, homes to that particular organ and repopulates its stem cell compartment, differentiating thus in what is seen as the organ-specific stem cell.
  • The gonads are the natural candidates for homing the primitive stem cells in adult organisms.
  • The model proposed in this work for the maintenance of organ-specific stem cell pools from an external source, represented by primitive, embryo-like germinal stem cells present in testes and ovaries, may contribute to the more complete understanding of this complex issue.
  • [MeSH-minor] Adult. Cell Differentiation. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15694702.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  •  go-up   go-down


57. Fuertes S, Setoain X, López-Guillermo A, Montserrat E, Fuster D, Paredes P, Lomeña F, Pons F: [The value of positron emission tomography/computed tomography (PET/CT) in the staging of diffuse large B-cell lymphoma]. Med Clin (Barc); 2007 Nov 17;129(18):688-93
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The value of positron emission tomography/computed tomography (PET/CT) in the staging of diffuse large B-cell lymphoma].
  • PATIENTS AND METHOD: Forty consecutive patients with diffuse large B-cell non Hodgkin lymphoma, were prospectively evaluated.
  • [MeSH-major] Lymphoma, B-Cell. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021609.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


58. Hallböök H, Hägglund H, Stockelberg D, Nilsson PG, Karlsson K, Björkholm M, Linderholm M, Wahlin A, Linder O, Smedmyr B, Swedish Adult ALL Group: Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group experience. Bone Marrow Transplant; 2005 Jun;35(12):1141-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group experience.
  • Adult patients with acute lymphoblastic leukaemia (ALL) have been treated according to national protocols in Sweden since 1986.
  • Stem cell transplantation (SCT) has been recommended in first remission for patients with risk factors for relapse, and for standard risk patients only after relapse.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Graft vs Host Disease. Graft vs Leukemia Effect. Humans. Male. Middle Aged. Philadelphia Chromosome. Probability. Recurrence. Retrospective Studies. Sweden. Tissue Donors. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15834433.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Greve J, Bas M, Schipper J, Hoffmann TK: [Primary cutane manifestation of a precursor-B-lymphoblastic lymphoma in the external ear]. Laryngorhinootologie; 2008 Oct;87(10):728-30
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cutane manifestation of a precursor-B-lymphoblastic lymphoma in the external ear].
  • We report on an extranodal B-cell-lymphoma of the ear in a young woman.
  • [MeSH-major] Ear Neoplasms / diagnosis. Ear, External. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Body Piercing / adverse effects. Combined Modality Therapy. Female. Humans. Radiotherapy, Adjuvant. Wound Infection / complications. Wound Infection / etiology. Young Adult

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633860.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


60. Goldstone AH, Rowe JM: Transplantation in adult ALL. Hematology Am Soc Hematol Educ Program; 2009;:593-601
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplantation in adult ALL.
  • The value of the allogeneic graft-versus-leukemia effect in adult acute lymphoblastic leukemia (ALL) has now been conclusively demonstrated and confirmed.
  • Clinical indications to harness the allogeneic effect will mature as the true value of pediatric protocols in adult patients and the safety and efficacy of a sibling, unrelated and reduced intensity transplant emerge in this disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20008244.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 44
  •  go-up   go-down


61. Goldstone AH: Transplants in Adult ALL--? Allo for everyone. Biol Blood Marrow Transplant; 2009 Jan;15(1 Suppl):7-10
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplants in Adult ALL--? Allo for everyone.
  • The large MRC/ECOG adult acute lymphoblastic leukemia (ALL) study establishes the value of sibling donor allogeneic transplant in standard-risk patients demonstrating superior outcome to conventional chemotherapy.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19147069.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


62. Yamaguchi T, Maeda Y, Ueda S, Hijikata Y, Morita Y, Miyatake JI, Matsuda M, Kanamaru A: Dichotomy of all-trans retinoic acid inducing signals for adult T-cell leukemia. Leukemia; 2005 Jun;19(6):1010-7
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dichotomy of all-trans retinoic acid inducing signals for adult T-cell leukemia.
  • We previously reported that all-trans retinoic acid (ATRA) inhibits growth in human T-cell leukemia virus type 1 (HTLV-1)-positive T-cell lines and fresh cells from patients with adult T-cell leukemia.
  • In the present study, we observed that NF-kappaB transcriptional activity as well as cell growth decreased significantly in HTLV-1-positive T-cell lines in the presence of ATRA.
  • SIL-2R was reduced by ATRA in both protein level (culture supernantant) and mRNA level in HTLV-1-positive T-cell lines.
  • Interestingly, ATRA significantly inhibited RT activity similar to azidothimidine (AZT) in HTLV-1-positive T-cell lines.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Leukemia, T-Cell / drug therapy. Leukemia, T-Cell / metabolism. Signal Transduction / drug effects. Tretinoin / pharmacology
  • [MeSH-minor] Adult. Cell Division / drug effects. Deltaretrovirus Infections / drug therapy. Deltaretrovirus Infections / metabolism. Deltaretrovirus Infections / physiopathology. Gene Expression Regulation, Leukemic / drug effects. Gene Expression Regulation, Viral / drug effects. Gene Products, gag / genetics. Gene Products, pol / genetics. Genes, pX / genetics. Human T-lymphotropic virus 1 / genetics. Human T-lymphotropic virus 1 / growth & development. Humans. In Vitro Techniques. Jurkat Cells. NF-kappa B / metabolism. Proviruses / genetics. Receptors, Interleukin-2 / metabolism. Solubility. Transcriptional Activation / drug effects. Viral Load

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15843825.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Gene Products, gag; 0 / Gene Products, pol; 0 / NF-kappa B; 0 / Receptors, Interleukin-2; 5688UTC01R / Tretinoin
  •  go-up   go-down


63. Gutiérrez MI, Siraj AK, Ibrahim MM, Hussain A, Bhatia K: Childhood and adult ALL: differences in epigenetic lesions associated with cell cycle genes. Am J Hematol; 2005 Oct;80(2):158-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood and adult ALL: differences in epigenetic lesions associated with cell cycle genes.
  • The impact of silencing tumor suppressor genes involved in cell proliferation in adult and pediatric ALL is still unknown.
  • Comparisons with adult ALL showed that p57 clearly differed in children (7% methylation) and adults (50% methylation).
  • While >20% of adult ALL Ph1 chromosome-negative undergo methylation of p73, p57, and p15, only 3% of childhood ALL carried such anomalies, which is very significant when a higher fraction of pediatric patients has non-Ph1 ALL than do the adult patients.
  • [MeSH-major] DNA Methylation. Genes, cdc. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Child. CpG Islands. Cyclin-Dependent Kinase Inhibitor p57. Epigenesis, Genetic. Genes, Tumor Suppressor. Humans. Nuclear Proteins / genetics. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16184585.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1C protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p57; 0 / Nuclear Proteins; 0 / RNA, Messenger
  •  go-up   go-down


64. Comitato R, Esposito T, Cerbo G, Angelini F, Varriale B, Cardone A: Impairment of spermatogenesis and enhancement of testicular germ cell apoptosis induced by exogenous all-trans-retinoic acid in adult lizard Podarcis sicula. J Exp Zool A Comp Exp Biol; 2006 Mar 1;305(3):288-98
Hazardous Substances Data Bank. TESTOSTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impairment of spermatogenesis and enhancement of testicular germ cell apoptosis induced by exogenous all-trans-retinoic acid in adult lizard Podarcis sicula.
  • Daily intraperitoneal injections of atRA or atRA plus testosterone (atRA+T) were given for 2 weeks to adult males of the lizard Podarcis sicula.
  • These effects are not completely inhibited by simultaneous administration of testosterone, although this hormone, once injected, is able to stimulate spermatogenesis and protect germinal cells from apoptotic cell death.
  • [MeSH-minor] Animals. Blotting, Northern. Cell Proliferation / drug effects. Histocytochemistry. In Situ Nick-End Labeling. Male. Organ Size / drug effects. RNA / chemistry. RNA / genetics. Random Allocation. Receptors, Retinoic Acid / genetics. Receptors, Retinoic Acid / physiology. Testosterone / pharmacology

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16432891.001).
  • [ISSN] 1548-8969
  • [Journal-full-title] Journal of experimental zoology. Part A, Comparative experimental biology
  • [ISO-abbreviation] J. Exp. Zoolog. Part A Comp. Exp. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Retinoic Acid; 3XMK78S47O / Testosterone; 5688UTC01R / Tretinoin; 63231-63-0 / RNA
  •  go-up   go-down


65. Beltran Gárate B, Morales Luna D, Quiñones Avila P, Hurtado de Mendoza F, Riva Gonzales L, Yabar A, Portugal Meza K: [Primary colorectal lymphoma of diffuse large B-cells: an experience at a general hospital]. Rev Gastroenterol Peru; 2008 Jul-Sep;28(3):235-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Colorectal Neoplasms. Lymphoma, Large B-Cell, Diffuse
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cecum / pathology. Colon / pathology. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Rectum / pathology. Retrospective Studies. Time Factors. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18958138.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Peru
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


66. Schultz SS, Abraham S, Lucas PA: Stem cells isolated from adult rat muscle differentiate across all three dermal lineages. Wound Repair Regen; 2006 Mar-Apr;14(2):224-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cells isolated from adult rat muscle differentiate across all three dermal lineages.
  • Adult stem cells capable of differentiating into phenotypes from all three dermal layers were isolated from adult rat muscle.
  • The results show that adult muscle contains pluripotent stem cells capable of differentiating across all three dermal lineages.
  • [MeSH-major] Cell Differentiation / physiology. Muscle, Skeletal / cytology. Stem Cells / physiology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630113.001).
  • [ISSN] 1067-1927
  • [Journal-full-title] Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
  • [ISO-abbreviation] Wound Repair Regen
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


67. Ségbéna AY, Prince-David M, Kagoné TS, Dagnra AY: [Human immunodeficiency virus, hepatitis C virus and hepatitis B viruses in patients with sickle-cell disease in Togo]. Transfus Clin Biol; 2005 Dec;12(6):423-6
MedlinePlus Health Information. consumer health - Sickle Cell Anemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Human immunodeficiency virus, hepatitis C virus and hepatitis B viruses in patients with sickle-cell disease in Togo].
  • CONTEXT: The clinical features of sickle cell disease (SCD) are vaso-occlusive and/or hemolytic crises which treatment may require blood transfusions.
  • [MeSH-major] Anemia, Sickle Cell / complications. Anemia, Sickle Cell / therapy. Blood Transfusion / adverse effects. HIV Infections / blood. HIV Infections / epidemiology. Hepatitis B / epidemiology. Hepatitis C / epidemiology
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / epidemiology. Adolescent. Adult. Child. Child, Preschool. Enzyme-Linked Immunosorbent Assay. Homozygote. Humans. Infant. Prevalence. Risk. Togo / epidemiology


68. Gleissner B, Goekbuget N, Rieder H, Arnold R, Schwartz S, Diedrich H, Schoch C, Heinze B, Fonatsch C, Bartram CR, Hoelzer D, Thiel E, GMALL Study Group: CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL). Blood; 2005 Dec 15;106(13):4054-6
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL).
  • Immunophenotyping disclosed CD10 negativity in 70 of 2408 cases of B-lineage acute lymphoblastic leukemia (ALL), although other criteria followed classification of pre-B ALL (eg, cytoplasmic immunoglobulin positivity).
  • Although 83% of the patients achieved complete remission, the remission duration remained remarkably low: 141 days for MLL rearrangement-positive and 245 days for MLL rearrangement-negative CD10(-) pre-B ALL.
  • Thus, the overall survival probability 3 years after diagnosis was 0.34 +/- 0.20 SE in MLL-rearrangement-negative versus 0.12 +/- 0.06 SE in MLL rearrangement-positive CD10- pre-B ALL.
  • Our data identify CD10- cytoplasmic immunoglobulin-positive pre-B ALL as a rare (2.2%) but distinct immuno-subtype of adult ALL that is characterized by a high MLL rearrangement rate and a worse outcome.
  • [MeSH-major] Chromosome Aberrations. Neprilysin / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosomes, Human, Pair 11 / genetics. Female. Germany. Humans. Male. Middle Aged. Risk Factors. Survival Rate. Transcription, Genetic / genetics. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16123216.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


69. Marzinke MA, Henderson EM, Yang KS, See AW, Knutson DC, Clagett-Dame M: Calmin expression in embryos and the adult brain, and its regulation by all-trans retinoic acid. Dev Dyn; 2010 Feb;239(2):610-9
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calmin expression in embryos and the adult brain, and its regulation by all-trans retinoic acid.
  • In embryonic day 18.5 embryos, CLMN is detected in regions where newly differentiated neurons are found, including the neural retina and the cortical plate; and in the adult brain, CLMN is most highly expressed in the neuron cell bodies of the hippocampus, cerebellum, and olfactory bulb.
  • Thus, Clmn is sensitive to retinoid status during early gestational stages, and its expression is relegated to postmitotic neuronal cells in the adult rat brain.
  • [MeSH-minor] Animals. Cell Line, Tumor. Down-Regulation. Gene Library. Immunoblotting. Immunohistochemistry. In Situ Hybridization. Mice. Microfilament Proteins. RNA, Messenger / metabolism. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20014094.001).
  • [ISSN] 1097-0177
  • [Journal-full-title] Developmental dynamics : an official publication of the American Association of Anatomists
  • [ISO-abbreviation] Dev. Dyn.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLMN protein, rat; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / RNA, Messenger; 5688UTC01R / Tretinoin
  •  go-up   go-down


70. Fauquier T, Rizzoti K, Dattani M, Lovell-Badge R, Robinson IC: SOX2-expressing progenitor cells generate all of the major cell types in the adult mouse pituitary gland. Proc Natl Acad Sci U S A; 2008 Feb 26;105(8):2907-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SOX2-expressing progenitor cells generate all of the major cell types in the adult mouse pituitary gland.
  • The pituitary gland adapts the proportion of each of its endocrine cell types to meet differing hormonal demands throughout life.
  • There is circumstantial evidence that multipotent adult progenitor cells contribute to this plasticity, but these cells have not been identified.
  • Here, we describe a small (<0.05%) population of progenitor cells in the adult pituitary gland.
  • We show that these cells express SOX2, a marker of several early embryonic progenitor and stem cell types, and form "pituispheres" in culture, which can grow, form secondary spheres, and differentiate to all of the pituitary endocrine cell types, as well as folliculostellate cells.
  • Cells expressing SOX2 and E-cadherin are found throughout Rathke's pouch (RP) in embryos but persist in the adult gland, mostly in a narrow zone lining the pituitary cleft, but also are scattered throughout the pituitary.
  • However, unlike in embryonic RP, most of these SOX2(+) cells in the adult gland also express SOX9 and S100.
  • We suggest that this SOX2(+)/SOX9(+) population represents transit-amplifying cells, whereas the SOX2(+)/SOX9(-) cells we identify are multipotent progenitor/stem cells persisting in the adult pituitary.
  • [MeSH-major] Cell Differentiation / physiology. DNA-Binding Proteins / metabolism. HMGB Proteins / metabolism. Pituitary Gland / cytology. Stem Cells / cytology. Transcription Factors / metabolism


71. Oda H, Yoshida Y, Kawamura A, Kakinuma A: Cell shape, cell-cell contact, cell-extracellular matrix contact and cell polarity are all required for the maximum induction of CYP2B1 and CYP2B2 gene expression by phenobarbital in adult rat cultured hepatocytes. Biochem Pharmacol; 2008 Mar 1;75(5):1209-17
Hazardous Substances Data Bank. Phenobarbital .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell shape, cell-cell contact, cell-extracellular matrix contact and cell polarity are all required for the maximum induction of CYP2B1 and CYP2B2 gene expression by phenobarbital in adult rat cultured hepatocytes.
  • The effect of cell shape, cell density, contact with extracellular matrix and cell polarity on the phenobarbital (PB)-induced gene expression of CYP2B1 and CYP2B2 (CYP2B1/2B2) in adult rat hepatocytes was investigated.
  • High cell density enhanced the induction of CYP2B1/2B2 gene expression by PB.
  • Hepatocytes cultured on EHS gel showed a spherical cell shape and highly enhanced the induction of CYP2B1/2B2 gene expression by PB.
  • EHS gel overlay to hepatocytes cultured on TIC and collagen sandwich configurations that are known to induce cell polarity enhanced the induction by PB.
  • These results demonstrate that cell shape, cell density, contact with extracellular matrix and cell polarity all play critical roles in the induction of CYP2B1/2B2 gene expression by PB.
  • [MeSH-minor] Animals. Cell Communication. Cell Count. Cell Polarity. Cell Shape. Cells, Cultured. Collagen Type I. Collagen Type IV. Extracellular Matrix. Gels. Gene Expression Regulation / drug effects. Laminin. Male. Rats. Rats, Wistar

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164277.001).
  • [ISSN] 1873-2968
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Collagen Type I; 0 / Collagen Type IV; 0 / Gels; 0 / Laminin; EC 1.14.- / Steroid Hydroxylases; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / Cytochrome P-450 CYP2B1; EC 1.14.14.1 / steroid 16-beta-hydroxylase; YQE403BP4D / Phenobarbital
  •  go-up   go-down


72. Nowak NJ, Sait SN, Zeidan A, Deeb G, Gaile D, Liu S, Ford L, Wallace PK, Wang ES, Wetzler M: Recurrent deletion of 9q34 in adult normal karyotype precursor B-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2010 May;199(1):15-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent deletion of 9q34 in adult normal karyotype precursor B-cell acute lymphoblastic leukemia.
  • The prognosis of adult normal karyotype (NK) precursor B-cell acute lymphoblastic leukemia (B-ALL) has not improved over the last decade, mainly because separation into distinct molecular subsets has been lacking and no targeted treatments are available.
  • We screened the genome of blasts from 10 adult NK B-ALL patients for novel genomic alterations by array comparative genomic hybridization and verified our results with fluorescent in situ hybridization and gene expression profile with the same probes.
  • This aberration has not been described before in adult NK B-ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • [Cites] Mol Biol Cell. 2000 Oct;11(10):3381-96 [11029043.001]
  • [Cites] J Hematol Oncol. 2009;2:3 [19166587.001]
  • [Cites] Nat Genet. 2001 Nov;29(3):263-4 [11687795.001]
  • [Cites] Blood. 2002 Jan 1;99(1):252-7 [11756179.001]
  • [Cites] Eur J Haematol. 2003 Jun;70(6):363-72 [12756018.001]
  • [Cites] Int Immunol. 2004 Oct;16(10):1377-89 [15302850.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Haematologica. 2007 Feb;92(2):232-5 [17296573.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1258-66 [17443227.001]
  • [Cites] Genet Med. 2007 Sep;9(9):585-95 [17873646.001]
  • [Cites] Br J Haematol. 2008 Mar;140(5):572-7 [18275435.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Curr Protoc Hum Genet. 2005 Aug;Chapter 4:Unit 4.13 [18428377.001]
  • [Cites] Blood. 2008 May 1;111(9):4668-80 [18299449.001]
  • [Cites] Leuk Res. 2008 Aug;32(8):1228-35 [18328560.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 6;105(18):6708-13 [18458336.001]
  • [Cites] Curr Opin Hematol. 2008 Jul;15(4):400-7 [18536580.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Sep;14(3):593-607 [11640871.001]
  • (PMID = 20417863.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016056; None / None / / P30 CA016056-33; United States / NCI NIH HHS / CA / CA16056; United States / NCI NIH HHS / CA / P30 CA016056-33
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Homeodomain Proteins; 157907-48-7 / HoxA protein
  • [Other-IDs] NLM/ NIHMS173834; NLM/ PMC2862995
  •  go-up   go-down


73. Maeda Y, Yamaguchi T, Hijikata Y, Tanaka M, Hirase C, Takai S, Morita Y, Sano T, Miyatake J, Tatsumi Y, Kanamaru A: Clinical efficacy of all-trans retinoic acid for treating adult T cell leukemia. J Cancer Res Clin Oncol; 2008 Jun;134(6):673-7
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical efficacy of all-trans retinoic acid for treating adult T cell leukemia.
  • PURPOSE: We previously reported that all-trans retinoic acid (ATRA) inhibited growth in human T-cell leukemia virus type I (HTLV-I)-positive T-cell lines and in fresh cells from patients with adult T cell leukemia (ATL).
  • In seven acute-type ATL patients, a PR was achieved in two (28.5%), NC was observed in two (28.5%), and a PD was observed in three (42.8%).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1997 Mar;11(3):401-7 [9067580.001]
  • [Cites] Virus Res. 2001 Oct 30;78(1-2):79-92 [11520582.001]
  • [Cites] Bone Marrow Transplant. 1987 Dec;2(4):441-4 [3332192.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):181-93 [11902573.001]
  • [Cites] Br J Haematol. 1994 Oct;88(2):403-5 [7803291.001]
  • [Cites] Leukemia. 1994;8 Suppl 3:S50-4 [7808025.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1797-8 [7564532.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):182-6 [8680890.001]
  • [Cites] Presse Med. 1990 Apr 21;19(16):746-51 [2140159.001]
  • [Cites] Leuk Res. 2001 Apr;25(4):323-31 [11248329.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):587-95 [15695403.001]
  • [Cites] Leuk Lymphoma. 2000 Oct;39(3-4):373-83 [11342318.001]
  • [Cites] Br J Haematol. 2000 Jun;109(3):677-8 [10886230.001]
  • [Cites] Biochim Biophys Acta. 1980 Mar 12;605(1):33-91 [6989400.001]
  • [Cites] Leukemia. 2004 Jun;18(6):1159-60 [15085162.001]
  • [Cites] Int J Hematol. 2000 Oct;72(3):343-5 [11185991.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] Leukemia. 2005 Jun;19(6):1010-7 [15843825.001]
  • [Cites] Blood. 1996 Dec 15;88(12):4726-7 [8977268.001]
  • [Cites] Leuk Res. 2000 Mar;24(3):265-6 [10739010.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):1-8 [10389969.001]
  • [Cites] Br J Haematol. 1996 Sep;94(4):713-5 [8826899.001]
  • [Cites] J Clin Oncol. 1992 May;10(5):839-64 [1569455.001]
  • [Cites] BioDrugs. 1998 Dec;10(6):447-62 [18020614.001]
  • (PMID = 18008086.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


74. Reina J, Plasencia V, Leyes M, Nicolau A, Galmés A, Arbona G: [Comparison study of a real-time reverse transcription polymerase chain reaction assay with an enzyme immunoassay and shell vial culture for influenza A and B virus detection in adult patients]. Enferm Infecc Microbiol Clin; 2010 Feb;28(2):95-8
MedlinePlus Health Information. consumer health - Flu.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison study of a real-time reverse transcription polymerase chain reaction assay with an enzyme immunoassay and shell vial culture for influenza A and B virus detection in adult patients].
  • However, in the adult population and using throat swabs, these techniques are much less reliable.
  • Each sample was inoculated into 2 SV of the MDCK cell line.
  • CONCLUSION: The real-time RT-PCR method studied displayed high sensitivity and specificity in the detection of influenza virus in adult patients, when compared with the conventional techniques.
  • [MeSH-minor] Adult. Animals. Cell Line / virology. Dogs. Fluorescent Antibody Technique, Indirect. Humans. Prospective Studies. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Elsevier España, S.L. All rights reserved.
  • (PMID = 19477042.001).
  • [ISSN] 1578-1852
  • [Journal-full-title] Enfermedades infecciosas y microbiología clínica
  • [ISO-abbreviation] Enferm. Infecc. Microbiol. Clin.
  • [Language] spa
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / RNA, Viral
  •  go-up   go-down


75. Chappaz S, Flueck L, Farr AG, Rolink AG, Finke D: Increased TSLP availability restores T- and B-cell compartments in adult IL-7 deficient mice. Blood; 2007 Dec 1;110(12):3862-70
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased TSLP availability restores T- and B-cell compartments in adult IL-7 deficient mice.
  • Interleukin 7 (IL-7) plays a crucial role in adult lymphopoiesis, while in fetal life its effect can be partially compensated by TSLP.
  • Whether adult hematopoietic progenitor cells are unresponsive to TSLP or whether TSLP is less available in adult microenvironments is still a matter of debate.
  • Here, we show that increased TSLP availability through transgene (Tg) expression fully restored lymphopoiesis in IL-7-deficient mice: it rescued B-cell development, increased thymic and splenic cellularities, and restored double-negative (DN) thymocytes, alphabeta and gammadelta T-cell generation, and all peripheral lymphoid compartments.
  • Analysis of bone marrow chimeras demonstrated that hematopoietic progenitor cells from adult wild-type mice efficiently differentiated toward B- and T-cell lineages in lethally irradiated IL-7 deficient mice provided TSLP Tg was expressed in these mice.
  • In vitro, TSLP promoted the differentiation of uncommitted adult bone marrow progenitors toward B and T lineages and the further differentiation of DN1 and DN2 thymocytes.
  • Altogether, our results show that adult hematopoietic cells are TSLP responsive and that TSLP can sustain long-term adult lymphopoiesis.
  • [MeSH-minor] Animals. Bone Marrow Transplantation. Cell Differentiation / genetics. Mice. Mice, Knockout. Receptors, Antigen, T-Cell, alpha-beta / genetics. Receptors, Antigen, T-Cell, alpha-beta / metabolism. Thymus Gland / metabolism. Transgenes / physiology. Transplantation Chimera

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17702899.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-7; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / thymic stromal lymphopoietin
  •  go-up   go-down


76. Asnafi V, Buzyn A, Le Noir S, Baleydier F, Simon A, Beldjord K, Reman O, Witz F, Fagot T, Tavernier E, Turlure P, Leguay T, Huguet F, Vernant JP, Daniel F, Béné MC, Ifrah N, Thomas X, Dombret H, Macintyre E: NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood; 2009 Apr 23;113(17):3918-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study.
  • Many somatic genetic abnormalities have been identified in T-cell acute lymphoblastic leukemia (T-ALL) but each individual abnormality accounts for a small proportion of cases; therapeutic stratification consequently still relies on classical clinical markers.
  • We screened 141 adult diagnostic T-ALL samples from patients treated on either the Lymphoblastic Acute Leukemia in Adults (LALA)-94 (n = 87) or the GRAALL-2003 (n = 54) trials.
  • [MeSH-major] Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / classification. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptor, Notch1 / genetics. Ubiquitin-Protein Ligases / genetics
  • [MeSH-minor] Adult. Genotype. Humans. Mutation / genetics. Phenotype. Prognosis. Societies, Medical. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19109228.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / Receptor, Notch1; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


77. Teachey DT, Obzut DA, Cooperman J, Fang J, Carroll M, Choi JK, Houghton PJ, Brown VI, Grupp SA: The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood; 2006 Feb 1;107(3):1149-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL.
  • Acute lymphoblastic leukemia (ALL) in adult patients is often resistant to current therapy, making the development of novel therapeutic agents paramount.
  • Lymphoblasts from adult patients with precursor B ALL were cultured on bone marrow stroma and were treated with CCI-779, a second generation MTI.
  • Treated cells showed a dramatic decrease in cell proliferation and an increase in apoptotic cells, compared to untreated cells.
  • We conclude that MTIs can inhibit the growth of adult human ALL and deserve close examination as therapeutic agents against a disease that is often not curable with current therapy.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Antibiot (Tokyo). 1984 Oct;37(10):1231-7 [6501094.001]
  • [Cites] J Antibiot (Tokyo). 1975 Oct;28(10):727-32 [1102509.001]
  • [Cites] Lancet. 1989 Jul 22;2(8656):227 [2568561.001]
  • [Cites] Science. 1991 Jan 18;251(4991):283-7 [1702904.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 10;91(10):4441-5 [8183928.001]
  • [Cites] Leukemia. 1994 Jul;8(7):1116-23 [7913512.001]
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):178-85 [9293448.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):907-13 [9508172.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5033-8 [9560223.001]
  • [Cites] Leuk Lymphoma. 1998 Sep;31(1-2):143-9 [9720724.001]
  • [Cites] Br J Haematol. 1998 Aug;102(3):718-21 [9722298.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):886-94 [10029080.001]
  • [Cites] Stem Cells. 2004;22(6):1111-20 [15536200.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):525-37 [15728109.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2825-31 [15805283.001]
  • [Cites] Cancer Treat Rev. 1981 Mar;8(1):63-87 [7248995.001]
  • [Cites] Leukemia. 2000 Sep;14(9):1614-20 [10995008.001]
  • [Cites] Cell. 2000 Oct 13;103(2):253-62 [11057898.001]
  • [Cites] Kidney Int. 2001 Jan;59(1):3-16 [11135052.001]
  • [Cites] Pediatr Hematol Oncol. 2000 Dec;17(8):635-50 [11127395.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6680-6 [11426655.001]
  • [Cites] Endocr Relat Cancer. 2001 Sep;8(3):249-58 [11566616.001]
  • [Cites] Am J Kidney Dis. 2001 Oct;38(4 Suppl 2):S22-8 [11583941.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6172-80 [11593425.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(16):2121-8 [11597394.001]
  • [Cites] Blood. 2002 Jul 15;100(2):654-60 [12091361.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):114-41; discussion 200-2 [12196212.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2887-92 [12912932.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15113-8 [14657335.001]
  • [Cites] Cancer Treat Rev. 2004 Feb;30(1):37-51 [14766125.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):657-66 [14770419.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):909-18 [14990647.001]
  • [Cites] Blood. 2004 May 15;103(10):3905-14 [14764536.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2336-47 [15136596.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1145-50 [15126317.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36490-6 [15218033.001]
  • [Cites] Br J Cancer. 2004 Oct 18;91(8):1420-4 [15365568.001]
  • [Cites] Leuk Res. 1986;10(8):1007-13 [3528680.001]
  • (PMID = 16195324.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / K08 CA104882; United States / NCI NIH HHS / CA / K08 CA104882-01A1; United States / NCI NIH HHS / CA / CA82156; United States / NCI NIH HHS / CA / CA104882-01A1; United States / NCI NIH HHS / CA / CA96696
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 624KN6GM2T / temsirolimus; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC1895910
  •  go-up   go-down


78. Jahrsdorfer B, Mühlenhoff L, Blackwell SE, Wagner M, Poeck H, Hartmann E, Jox R, Giese T, Emmerich B, Endres S, Weiner GJ, Hartmann G: B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res; 2005 Feb 15;11(4):1490-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.
  • Synthetic CpG oligodeoxynucleotides are currently being tested in clinical trials for the therapy of different types of B cell non-Hodgkin's lymphoma.
  • Here we found that most B-cell malignancies except plasmacytoma respond to CpG oligodeoxynucleotides by up-regulating expression of costimulatory and antigen-presenting molecules, by increasing expression of CD20, and by proliferation.
  • In an in vitro analysis of 41 individual patient-derived primary tumor samples, B-cell chronic lymphocytic leukemia (B-CLL) and marginal zone lymphoma showed the strongest activation upon stimulation with CpG oligodeoxynucleotides.
  • Small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, and large cell lymphoma showed an intermediate response.
  • Although CpG oligodeoxynucleotides induced proliferation in all CpG oligodeoxynucleotide-sensitive types of B-cell malignancies, proliferation was weaker than in normal B cells and at least for B-CLL was followed by increased apoptosis.
  • In conclusion, B-cell malignancies show significant differences in their responsiveness to CpG oligodeoxynucleotides.
  • Focusing clinical studies on patients with highly CpG oligodeoxynucleotide-sensitive B-cell malignancies may improve the clinical outcome of such trials.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Oligodeoxyribonucleotides / pharmacology
  • [MeSH-minor] Adjuvants, Immunologic / pharmacology. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / biosynthesis. Antigens, CD20 / immunology. Cell Proliferation / drug effects. Cell Survival / drug effects. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Membrane Glycoproteins / genetics. Middle Aged. Plasmacytoma / drug therapy. Plasmacytoma / genetics. Plasmacytoma / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Cell Surface / genetics. Rituximab. Time Factors. Toll-Like Receptor 9. Toll-Like Receptors. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15746051.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / CPG-oligonucleotide; 0 / Membrane Glycoproteins; 0 / Oligodeoxyribonucleotides; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / TLR9 protein, human; 0 / Toll-Like Receptor 9; 0 / Toll-Like Receptors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


79. Terwey TH, Massenkeil G, Tamm I, Hemmati PG, Neuburger S, Martus P, Dörken B, Hoelzer D, Arnold R: Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy. Bone Marrow Transplant; 2008 Dec;42(12):791-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy.
  • We present 60 patients with refractory (n=8) or relapsed (n=52) adult ALL who received allogeneic hematopoietic SCT (HSCT) with (n=41) or without (n=19) prior reinduction chemotherapy.
  • Leukemia-free survival at 1, 2 and 5 years was 37, 33 and 24%.
  • Deaths were due to relapse (n=25), acute or chronic GVHD (n=7), infections (n=8) or toxicity (n=4).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Neoplasm Recurrence, Local / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Drug Resistance, Neoplasm. Drug Therapy / utilization. Female. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18711350.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


80. Giebel S, Stella-Holowiecka B, Krawczyk-Kulis M, Gökbuget N, Hoelzer D, Doubek M, Mayer J, Piatkowska-Jakubas B, Skotnicki AB, Dombret H, Ribera JM, Piccaluga PP, Czerw T, Kyrcz-Krzemien S, Holowiecki J, Study Group for Adult ALL of the European Leukemia Net: Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL. Bone Marrow Transplant; 2010 Jun;45(6):1095-101

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL.
  • The role of autologous hematopoietic SCT (autoHSCT) in the treatment of high-risk (HR) adult ALL is controversial.
  • In this study, we retrospectively analyzed the results of autoHSCT according to the status of minimal residual disease (MRD) at transplantation, as a joint analysis of the European Study Group for Adult ALL (EWALL).
  • In a cohort of Ph-negative ALL, the probability of leukemia-free survival at 5 years was higher for patients with MRD <0.1% compared with those with MRD > or = 0.1% (57 vs 17%, P=0.0002).
  • We conclude that MRD determines the outcome of autoHSCT in HR adult ALL.
  • [MeSH-major] Neoplasm, Residual. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Disease-Free Survival. Hematopoietic Stem Cell Transplantation. Humans. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Transplantation, Autologous. Treatment Failure. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19855438.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


81. Yan X, Bellotto DJ, Dane DM, Elmore RG, Johnson RL Jr, Estrera AS, Hsia CC: Lack of response to all-trans retinoic acid supplementation in adult dogs following left pneumonectomy. J Appl Physiol (1985); 2005 Nov;99(5):1681-8
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of response to all-trans retinoic acid supplementation in adult dogs following left pneumonectomy.
  • We showed previously that removing 55-58% of the lung by right pneumonectomy (R-PNX) in adult dogs triggers compensatory growth of the remaining lung, but removing 42-45% of the lung by left PNX (L-PNX) does not.
  • We also showed that, following R-PNX, supplemental all-trans retinoic acid (RA) selectively enhances alveolar capillary endothelial cell volume (Yan X, Bellotto DJ, Foster DJ, Johnson RL, Jr., Hagler HH, Estrera AS, and Hsia CC.
  • We hypothesized that RA supplementation might enhance compensation following L-PNX and tested this hypothesis by administering RA (2 mg.kg(-1).day(-1), 4 days/wk) or placebo orally to litter-matched adult foxhounds for 4 mo following L-PNX.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15961609.001).
  • [ISSN] 8750-7587
  • [Journal-full-title] Journal of applied physiology (Bethesda, Md. : 1985)
  • [ISO-abbreviation] J. Appl. Physiol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL-040070; United States / NHLBI NIH HHS / HL / R01 HL-045716; United States / NHLBI NIH HHS / HL / R01 HL054060; United States / NHLBI NIH HHS / HL / HL-054060; United States / NHLBI NIH HHS / HL / R01 HL045716; United States / NHLBI NIH HHS / HL / HL-062873; United States / NHLBI NIH HHS / HL / R01 HL062873; United States / NHLBI NIH HHS / HL / R01 HL040070
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


82. Crupi R, Cambiaghi M, Spatz L, Hen R, Thorn M, Friedman E, Vita G, Battaglia F: Reduced adult neurogenesis and altered emotional behaviors in autoimmune-prone B-cell activating factor transgenic mice. Biol Psychiatry; 2010 Mar 15;67(6):558-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced adult neurogenesis and altered emotional behaviors in autoimmune-prone B-cell activating factor transgenic mice.
  • Accordingly, we examined emotional behaviors in autoimmune-prone cytokine B-cell-activating factor (BAFF) transgenic mice, a model of systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's syndrome.
  • Mice were also tested for brain inflammation, stress-induced c-Fos expression, hippocampal progenitor cell proliferation, and hippocampal neurogenesis-dependent and neurogenesis-independent long-term potentiation (LTP).
  • Proliferation of newly formed neurons in the subgranular zone of adult hippocampus was significantly decreased in anxious BAFF transgenic mice that also showed impaired neurogenesis-dependent and neurogenesis-independent dentate gyrus LTP.
  • [MeSH-major] Anxiety. B-Cell Activating Factor / genetics. Emotions / physiology. Encephalitis. Gene Expression Regulation / genetics. Neurogenesis / genetics
  • [MeSH-minor] Age Factors. Animals. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Behavior, Animal / physiology. Cell Proliferation. Disease Models, Animal. Electric Stimulation / methods. Enzyme-Linked Immunosorbent Assay / methods. Exploratory Behavior / physiology. Glial Fibrillary Acidic Protein / metabolism. Hindlimb Suspension / methods. Hippocampus / cytology. Immunoglobulin G / blood. In Vitro Techniques. Long-Term Potentiation / genetics. Male. Maze Learning / physiology. Mice. Mice, Inbred C57BL. Mice, Transgenic. Microtubule-Associated Proteins / metabolism. Neurons / physiology. Neuropeptides / metabolism. Proto-Oncogene Proteins c-fos / metabolism. Stem Cells / physiology. Swimming / psychology

  • MedlinePlus Health Information. consumer health - Anxiety.
  • MedlinePlus Health Information. consumer health - Encephalitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20185032.001).
  • [ISSN] 1873-2402
  • [Journal-full-title] Biological psychiatry
  • [ISO-abbreviation] Biol. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / B-Cell Activating Factor; 0 / CD68 antigen, human; 0 / Glial Fibrillary Acidic Protein; 0 / Immunoglobulin G; 0 / Microtubule-Associated Proteins; 0 / Neuropeptides; 0 / Proto-Oncogene Proteins c-fos; 0 / doublecortin protein
  •  go-up   go-down


83. Mu Y, Lee SW, Gage FH: Signaling in adult neurogenesis. Curr Opin Neurobiol; 2010 Aug;20(4):416-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signaling in adult neurogenesis.
  • Neural stem cells (NSCs) in the adult brain continuously supply new neurons to the hippocampal dentate gyrus (DG) and the olfactory bulb (OB).
  • Recent studies indicate that the progression from neural precursor cells (NPCs) to mature neurons is tightly controlled by coordinate cell-intrinsic programs and external signals within the neurogenic niche.
  • In this review, we summarize both classes of regulatory factors involved in distinct stages of adult neurogenesis, including proliferation and lineage differentiation of NSCs, migration of neuroblasts and integration of newborn neurons.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Neuron. 2007 May 24;54(4):559-66 [17521569.001]
  • [Cites] J Neurosci. 2007 May 30;27(22):5936-47 [17537964.001]
  • [Cites] J Neurosci. 2007 May 30;27(22):5976-80 [17537968.001]
  • [Cites] Eur J Neurosci. 2007 May;25(9):2591-603 [17466019.001]
  • [Cites] Eur J Neurosci. 2007 May;25(9):2581-90 [17561834.001]
  • [Cites] Neurobiol Dis. 2007 Jul;27(1):77-89 [17532643.001]
  • [Cites] Rev Neurosci. 2007;18(2):93-114 [17593874.001]
  • [Cites] Science. 2007 Jul 20;317(5836):381-4 [17615304.001]
  • [Cites] Eur J Neurosci. 2009 Sep;30(5):742-55 [19712103.001]
  • [Cites] Cell. 2009 Nov 13;139(4):814-27 [19914173.001]
  • [Cites] Glia. 2010 Jan 15;58(2):218-30 [19610095.001]
  • [Cites] Nat Neurosci. 2009 Dec;12(12):1524-33 [19881504.001]
  • [Cites] Nat Cell Biol. 2010 Jan;12(1):31-40; sup pp 1-9 [20010817.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1201-6 [20080708.001]
  • [Cites] Neuron. 2010 Mar 25;65(6):859-72 [20346761.001]
  • [Cites] Nat Rev Neurosci. 2010 May;11(5):339-50 [20354534.001]
  • [Cites] J Neurosci. 2007 Nov 21;27(47):12764-74 [18032648.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1433-8 [10688783.001]
  • [Cites] J Neurosci. 2000 Dec 1;20(23):8727-35 [11102479.001]
  • [Cites] Curr Biol. 2002 Apr 30;12(9):735-9 [12007417.001]
  • [Cites] Biol Psychiatry. 2007 Sep 1;62(5):381-90 [17239352.001]
  • [Cites] Cell. 2007 Sep 21;130(6):1146-58 [17825401.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15282-7 [17873065.001]
  • [Cites] Development. 2008 Feb;135(3):541-57 [18171687.001]
  • [Cites] Nature. 2008 Feb 21;451(7181):1004-7 [18235445.001]
  • [Cites] Cell. 2008 Feb 22;132(4):645-60 [18295581.001]
  • [Cites] Nat Neurosci. 2008 Mar;11(3):277-84 [18297065.001]
  • [Cites] J Neurosci. 2008 Mar 5;28(10):2383-93 [18322085.001]
  • [Cites] Nat Neurosci. 2008 Aug;11(8):888-93 [18587391.001]
  • [Cites] Genes Dev. 2008 Sep 15;22(18):2473-8 [18794344.001]
  • [Cites] Stem Cells. 2008 Sep;26(9):2311-20 [18617686.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15570-5 [18832146.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):515-28 [18371391.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18567-71 [19017796.001]
  • [Cites] PLoS Biol. 2008 Nov 11;6(11):e272 [18998770.001]
  • [Cites] Cell. 2009 Jan 23;136(2):215-33 [19167326.001]
  • [Cites] Science. 2009 Feb 20;323(5917):1074-7 [19119186.001]
  • [Cites] Nat Neurosci. 2009 Apr;12(4):399-408 [19287386.001]
  • [Cites] Nature. 2009 Mar 26;458(7237):529-33 [19212323.001]
  • [Cites] Nat Neurosci. 2009 Jun;12(6):728-30 [19412168.001]
  • [Cites] Stem Cells. 2009 May;27(5):1130-41 [19418460.001]
  • [Cites] J Neurosci. 2009 Jun 24;29(25):7966-77 [19553437.001]
  • [Cites] Science. 2009 Jul 10;325(5937):210-3 [19590004.001]
  • [Cites] J Neurosci. 2009 Aug 5;29(31):9875-87 [19657039.001]
  • [Cites] Nat Neurosci. 2009 Sep;12(9):1090-2 [19701197.001]
  • [Cites] Nat Neurosci. 2009 Sep;12(9):1097-105 [19701198.001]
  • [Cites] J Neurosci. 2002 Jul 15;22(14):6106-13 [12122071.001]
  • [Cites] Nat Neurosci. 2003 Jan;6(1):21-7 [12469128.001]
  • [Cites] Nat Neurosci. 2003 May;6(5):507-18 [12704391.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 27;100(11):6777-82 [12748381.001]
  • [Cites] Nature. 2004 Jan 1;427(6969):78-83 [14702088.001]
  • [Cites] Neuron. 2004 Mar 4;41(5):683-6 [15003168.001]
  • [Cites] Development. 2004 Aug;131(15):3805-19 [15240551.001]
  • [Cites] Science. 1994 May 20;264(5162):1145-8 [8178174.001]
  • [Cites] Science. 1996 Feb 16;271(5251):978-81 [8584933.001]
  • [Cites] J Neurosci. 1996 Mar 15;16(6):2027-33 [8604047.001]
  • [Cites] Nature. 1996 Oct 17;383(6601):624-7 [8857538.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1313-7 [9809557.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5768-73 [10318959.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16659-64 [15537713.001]
  • [Cites] Curr Opin Neurobiol. 2005 Oct;15(5):514-20 [16144763.001]
  • [Cites] Nature. 2005 Oct 27;437(7063):1370-5 [16251967.001]
  • [Cites] J Neurosci. 2005 Nov 2;25(44):10105-18 [16267218.001]
  • [Cites] J Neurosci. 2005 Nov 16;25(46):10729-39 [16291946.001]
  • [Cites] J Neurophysiol. 2005 Dec;94(6):4528-32 [16033936.001]
  • [Cites] Nature. 2006 Feb 2;439(7076):589-93 [16341203.001]
  • [Cites] Learn Mem. 2006 May-Jun;13(3):307-15 [16705139.001]
  • [Cites] Mol Cell Neurosci. 2006 May-Jun;32(1-2):187-98 [16730456.001]
  • [Cites] Nature. 2006 Aug 24;442(7105):929-33 [16906136.001]
  • [Cites] J Neurosci. 2006 Nov 1;26(44):11359-70 [17079664.001]
  • [Cites] J Neurosci. 2006 Dec 13;26(50):12956-66 [17167085.001]
  • [Cites] Genes Dev. 2007 Mar 1;21(5):531-6 [17344415.001]
  • (PMID = 20471243.001).
  • [ISSN] 1873-6882
  • [Journal-full-title] Current opinion in neurobiology
  • [ISO-abbreviation] Curr. Opin. Neurobiol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS050217-05; United States / NIMH NIH HHS / MH / R01 MH090258; United States / NIMH NIH HHS / MH / R01 MH090258-02; United States / NINDS NIH HHS / NS / R01 NS050217; United States / NIMH NIH HHS / MH / MH-090258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Transcription Factors
  • [Other-IDs] NLM/ NIHMS205387; NLM/ PMC2942965
  •  go-up   go-down


84. Rai L, Casanova A, Moorman AV, Richards S, Buck G, Goldstone AH, Fielding AK, Foroni L: Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cell-origin of ALL subgroups - a UKALLXII study. Br J Haematol; 2010 Feb;148(3):394-401
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cell-origin of ALL subgroups - a UKALLXII study.
  • Cytogenetic and molecular investigations of Acute Lymphoblastic Leukaemia (ALL) have identified the existence of distinct clinical subgroups.
  • Molecular monitoring of clonal Immunoglobulin and T cell receptor (IG/TR) gene rearrangements has become an important tool in stratification of therapy of ALL.
  • In order to determine whether certain features of the patient-specific rearrangements could hold further prognostic clues or provide information on the cell of origin of ALL, a comprehensive analysis of structural and biological features (V gene usage, coding frame and mutational status and complementarity-determining region -III length) of 473 IG/TR rearrangements identified in 229 adults with ALL was carried out.
  • [MeSH-major] Gene Rearrangement, T-Lymphocyte. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell / genetics
  • [MeSH-minor] Adolescent. Adult. Complementarity Determining Regions / genetics. Female. Humans. Immunoglobulin Variable Region / genetics. Immunophenotyping. Male. Middle Aged. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Prognosis. Translocation, Genetic. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19895613.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137686856; United Kingdom / Medical Research Council / / G8223452; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Complementarity Determining Regions; 0 / Immunoglobulin Variable Region; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


85. Saad AA, Awed NM, Abdel-Hafeez ZM, Kamal GM, Elsallaly HM, Alloub AI: Prognostic value of immunohistochemical classification of diffuse large B-cell lymphoma into germinal center B-cell and non-germinal center B-cell subtypes. Saudi Med J; 2010 Feb;31(2):135-41
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of immunohistochemical classification of diffuse large B-cell lymphoma into germinal center B-cell and non-germinal center B-cell subtypes.
  • OBJECTIVE: To study the expression of germinal center B-cell (GCB)/activated B-cell like-related proteins to get optimal stratification of diffuse large B-cell lymphoma (DLBCL) patients, and correlate this with the established clinical and laboratory parameters.
  • Each case included in this study was investigated by immunohistochemical reaction for multiple myeloma-1/interferon regulatory factor-4, B-cell/lymphoma 6, and cluster of differentiation10 monoclonal antibodies.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / classification
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20174727.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


86. Ortega-Perez I, Murray K, Lledo PM: The how and why of adult neurogenesis. J Mol Histol; 2007 Dec;38(6):555-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The how and why of adult neurogenesis.
  • Multiple and dissociable plastic changes in the adult brain involve many different levels of organization, ranging from molecules to systems, with changes in neural elements occurring hand-in-hand with changes in supportive tissue elements, such as glia cells and blood vessels.
  • "Is adult neurogenesis an atavism, an empty-running leftover from evolution?
  • What is adult neurogenesis good for and how does the brain 'know' that more neurons are needed?
  • How is this functional demand translated into signals a precursor cell can detect?
  • "[corrected].Adult neurogenesis may represent an adaptive response to challenges imposed by an environment and/or internal state of the animal.
  • [MeSH-major] Adult Stem Cells / physiology. Brain / physiology. Neurons / physiology. Olfactory Bulb / physiology
  • [MeSH-minor] Adult. Animals. Astrocytes / physiology. Cell Differentiation. Glial Fibrillary Acidic Protein / metabolism. Humans. Mice. Olfactory Pathways / cytology. Olfactory Pathways / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Mol Histol. 2010 Oct;41(4-5):307-8
  • (PMID = 17605077.001).
  • [ISSN] 1567-2379
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  • [Number-of-references] 59
  •  go-up   go-down


87. Baak U, Gökbuget N, Orawa H, Schwartz S, Hoelzer D, Thiel E, Burmeister T, German Multicenter ALL Study Group: Thymic adult T-cell acute lymphoblastic leukemia stratified in standard- and high-risk group by aberrant HOX11L2 expression: experience of the German multicenter ALL study group. Leukemia; 2008 Jun;22(6):1154-60
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymic adult T-cell acute lymphoblastic leukemia stratified in standard- and high-risk group by aberrant HOX11L2 expression: experience of the German multicenter ALL study group.
  • Adult T-cell acute lymphoblastic leukemia (T-ALL) continues to represent an unfavorable disease.
  • We have investigated 286 adult T-ALL patients enrolled into the German Multicenter ALL (GMALL) therapy protocols by comparative real-time RT-PCR.
  • [MeSH-major] Homeodomain Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Proto-Oncogene Proteins / genetics. Thymus Gland / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Risk Factors. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18368072.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / TLX3 protein, human; 143275-75-6 / TLX1 protein, human
  •  go-up   go-down


88. Larson R: Allogeneic hematopoietic cell transplantation for adults with ALL. Bone Marrow Transplant; 2008 Aug;42 Suppl 1:S18-S24
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic cell transplantation for adults with ALL.
  • Available data indicate no consensus as to whether there is an advantage to allogeneic hematopoietic cell transplant (Allo-HCT) over chemotherapy for the consolidation of adults with ALL with standard risk features while in the first CR (CR1).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Humans. Risk Assessment. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18724292.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 37
  •  go-up   go-down


89. Murawski N, Zwick C, Pfreundschuh M: Unresolved issues in diffuse large B-cell lymphomas. Expert Rev Anticancer Ther; 2010 Mar;10(3):387-402
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unresolved issues in diffuse large B-cell lymphomas.
  • For more than 25 years, the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was considered the 'gold standard' for the treatment of aggressive lymphomas, 90% of which are diffuse large B-cell lymphomas (DLBCLs).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Middle Aged. Prednisone / administration & dosage. Randomized Controlled Trials as Topic. Remission Induction / methods. Rituximab. Survival Rate. Treatment Outcome. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20214520.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 151
  •  go-up   go-down


90. Cedar SH: Stem cell and related therapies: nurses and midwives representing all parties. Nurs Ethics; 2006 May;13(3):292-303
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell and related therapies: nurses and midwives representing all parties.
  • Recent scientific advances have introduced new techniques of screening and diagnosis linked to stem cell isolation and therapies.
  • In this article stem cell techniques and therapies are outlined, as well as some of the ethical challenges faced by various nursing groups, whether in adult, learning difficulties, mental health, paediatric, primary care, public health or health visiting areas.
  • [MeSH-major] Cloning, Organism / ethics. Ethics, Nursing. Fertilization in Vitro / ethics. Stem Cell Transplantation / ethics

  • MedlinePlus Health Information. consumer health - Cloning.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16711188.001).
  • [ISSN] 0969-7330
  • [Journal-full-title] Nursing ethics
  • [ISO-abbreviation] Nurs Ethics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 28
  •  go-up   go-down


91. Soulier J, Clappier E, Cayuela JM, Regnault A, García-Peydró M, Dombret H, Baruchel A, Toribio ML, Sigaux F: HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood; 2005 Jul 1;106(1):274-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL).
  • Using a combination of molecular cytogenetic and large-scale expression analysis in human T-cell acute lymphoblastic leukemias (T-ALLs), we identified and characterized a new recurrent chromosomal translocation, targeting the major homeobox gene cluster HOXA and the TCRB locus.
  • Because T-ALLs derive from T-cell progenitors, expression profiles of the distinct T-ALL subgroups were analyzed with respect to those of normal human thymic subpopulations.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Homeodomain Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Differentiation / genetics. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Infant. Male. Middle Aged. Multigene Family. T-Lymphocytes / cytology. T-Lymphocytes / physiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15774621.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 157907-48-7 / HoxA protein
  •  go-up   go-down


92. Burmeister T, Gökbuget N, Reinhardt R, Rieder H, Hoelzer D, Schwartz S: NUP214-ABL1 in adult T-ALL: the GMALL study group experience. Blood; 2006 Nov 15;108(10):3556-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NUP214-ABL1 in adult T-ALL: the GMALL study group experience.
  • The NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia (T-ALL) has recently been identified as a possible target for imatinib and related tyrosine kinase inhibitors, but exact data regarding the prognostic impact and frequency of the several putative NUP214-ABL1 mRNA transcripts are still missing.
  • We investigated 279 adult patients with T-ALL treated within the framework of the GMALL 5/93 and 6/99 therapy trials for NUP214-ABL1 by using a novel multiplex real-time, quantitative polymerase chain reaction (PCR).
  • Eleven (3.9%) patients were NUP214-ABL1 positive, and 5 different transcripts were observed; 8 patients had a thymic immunophenotype, 1 had an early T-cell immunophenotype, and 2 had a mature T-cell immunophenotype.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / genetics. Nuclear Pore Complex Proteins / genetics. Oncogene Proteins, Fusion / genetics. Proto-Oncogene Proteins c-abl / genetics
  • [MeSH-minor] Adolescent. Adult. Benzamides. Female. Humans. Imatinib Mesylate. Immunophenotyping. Male. Piperazines / therapeutic use. Polymerase Chain Reaction. Prognosis. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use. RNA, Messenger / analysis. Survival Rate

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16873673.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / NUP214 protein, human; 0 / Nuclear Pore Complex Proteins; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Pyrimidines; 0 / RNA, Messenger; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Proto-Oncogene Proteins c-abl
  •  go-up   go-down


93. Lee DS, Kim YR, Cho HK, Lee CK, Lee JH, Cho HI: The presence of TEL/AML1 rearrangement and cryptic deletion of the TEL gene in adult acute lymphoblastic leukemia (ALL). Cancer Genet Cytogenet; 2005 Oct 15;162(2):176-8
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The presence of TEL/AML1 rearrangement and cryptic deletion of the TEL gene in adult acute lymphoblastic leukemia (ALL).
  • TEL/AML1 (also known as ETV6/RUNX1) rearrangement is the most frequent genetic change in childhood B-acute lymphoblastic leukemia (ALL) and is associated with a favorable prognosis.
  • Its presence in adult ALL, however, has been questionable, and any association between TEL/AML1 rearrangement and clinical prognosis is unknown.
  • To reveal the presence and incidence of the TEL/AML1 rearrangement in adult ALL, we applied fluorescence in situ hybridization (FISH).
  • We conducted extra-signal, dual-color fluorescence in situ hybridization (ES-FISH) for TEL/AML1 rearrangement on bone marrow cells from 74 adult ALL patients and analyzed the survival time.
  • Of 74 adult ALL patients, 3 (4.0%) showed deletion of the TEL gene without TEL/AML1 rearrangement.
  • TEL/AML1 rearrangement is not unique in childhood ALL, and cryptic TEL deletion without TEL/AML1 rearrangement was more frequent than the TEL/AML1 rearrangement in adult ALL.
  • We recommend TEL/AML1 FISH in adult ALL patients because conventional cytogenetic studies so far have yielded uninformative results.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Deletion. Gene Rearrangement. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16213368.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / ETS translocation variant 6 protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


94. Darwiche H, Petersen BE: Biology of the adult hepatic progenitor cell: "ghosts in the machine". Prog Mol Biol Transl Sci; 2010;97:229-49
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biology of the adult hepatic progenitor cell: "ghosts in the machine".
  • This chapter reviews some of the basic biological principles governing adult progenitor cells of the liver and the mechanisms by which they operate.
  • If scientists were better able to understand the conditions that govern stem cell mechanics in the liver, it may be possible to apply that understanding in a clinical setting for use in the treatment or cure of human pathologies.
  • This chapter gives a basic introduction to hepatic progenitor cell biology and explores what is known about progenitor cell-mediated liver regeneration.
  • We also discuss the putative stem cell niche in the liver, as well as the signaling pathways involved in stem cell regulation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Hepatology. 1996 Jan;23(1):71-9 [8550051.001]
  • [Cites] Gastroenterology. 1996 Apr;110(4):1182-90 [8613008.001]
  • [Cites] Hepatology. 1996 Mar;23(3):482-96 [8617428.001]
  • [Cites] Am J Pathol. 1996 Oct;149(4):1167-75 [8863666.001]
  • [Cites] Hepatology. 1998 Feb;27(2):433-45 [9462642.001]
  • [Cites] N Engl J Med. 1998 May 14;338(20):1422-6 [9580649.001]
  • [Cites] Lab Invest. 2007 Dec;87(12):1227-39 [17952094.001]
  • [Cites] Cell Tissue Res. 2008 Jan;331(1):283-300 [18046579.001]
  • [Cites] Dig Liver Dis. 2008 Jan;40(1):54-61 [17997371.001]
  • [Cites] Hepatology. 2008 Jan;47(1):288-95 [17929301.001]
  • [Cites] Hepatology. 2008 Feb;47(2):636-47 [18023068.001]
  • [Cites] Hepatology. 2008 Mar;47(3):996-1004 [18167060.001]
  • [Cites] Hepatology. 2008 May;47(5):1544-56 [18393293.001]
  • [Cites] Semin Liver Dis. 2008 May;28(2):210-7 [18452120.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1532-43 [18471524.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4287-95 [18519688.001]
  • [Cites] Hepatology. 2008 Jun;47(6):1994-2002 [18454509.001]
  • [Cites] Regen Med. 2008 Jul;3(4):575-95 [18588477.001]
  • [Cites] Gut. 2008 Aug;57(8):1129-38 [18417531.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Aug;295(2):C499-513 [18508907.001]
  • [Cites] Liver Int. 2008 Sep;28(8):1052-64 [18783548.001]
  • [Cites] Hepatology. 2008 Oct;48(4):1282-91 [18726953.001]
  • [Cites] Hepatology. 2008 Nov;48(5):1598-607 [18972441.001]
  • [Cites] J Pathol. 2009 Jan;217(2):282-98 [18991329.001]
  • [Cites] Hepatology. 2009 Jan;49(1):318-29 [19111019.001]
  • [Cites] Expert Rev Mol Med. 2009;11:e7 [19239726.001]
  • [Cites] Hepatology. 2009 Mar;49(3):920-9 [19105206.001]
  • [Cites] Gut. 2009 Apr;58(4):594-603 [19091822.001]
  • [Cites] Stem Cell Res. 2007 Nov;1(2):90-102 [19383389.001]
  • [Cites] Hepatology. 2009 May;49(5):1625-35 [19296469.001]
  • [Cites] Development. 2009 Jun;136(11):1951-60 [19429791.001]
  • [Cites] Toxicol In Vitro. 2009 Jun;23(4):748-53 [19328226.001]
  • [Cites] J Hepatol. 1999 Nov;31(5):965-6 [10580599.001]
  • [Cites] J Pathol. 2000 May;191(1):78-85 [10767723.001]
  • [Cites] J Pathol. 2000 Nov;192(3):373-8 [11054721.001]
  • [Cites] J Exp Med. 2000 Dec 18;192(12):1809-18 [11120777.001]
  • [Cites] Hepatology. 2001 Mar;33(3):738-50 [11230756.001]
  • [Cites] J Cell Biol. 1998 Nov 16;143(4):1101-12 [9817765.001]
  • [Cites] Science. 1999 May 14;284(5417):1168-70 [10325227.001]
  • [Cites] Hepatology. 1999 Jul;30(1):112-7 [10385646.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5):1525-39 [15521020.001]
  • [Cites] Wound Repair Regen. 2004 Nov-Dec;12(6):650-6 [15555057.001]
  • [Cites] Transplantation. 2004 Dec 27;78(12):1812-4 [15614156.001]
  • [Cites] Hepatology. 2005 Feb;41(2):327-35 [15660390.001]
  • [Cites] Hepatology. 2005 Apr;41(4):906-15 [15799032.001]
  • [Cites] Gastroenterology. 2005 Jun;128(7):2077-88 [15940639.001]
  • [Cites] J Clin Invest. 2005 Sep;115(9):2330-40 [16110324.001]
  • [Cites] Dig Surg. 2005;22(4):254-64 [16174982.001]
  • [Cites] Curr Opin Rheumatol. 2006 Jan;18(1):64-73 [16344621.001]
  • [Cites] APMIS. 2005 Nov-Dec;113(11-12):876-902 [16480456.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1880-5 [16574858.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 May;290(5):G859-70 [16322088.001]
  • [Cites] Nat Rev Genet. 2006 May;7(5):349-59 [16619050.001]
  • [Cites] Lancet. 2006 Apr 15;367(9518):1241-6 [16631879.001]
  • [Cites] Cell Mol Life Sci. 2006 Apr;63(7-8):760-6 [16568245.001]
  • [Cites] J Hepatol. 2006 Jul;45(1):1-4 [16723168.001]
  • [Cites] Circulation. 2006 Jul 4;114(1 Suppl):I132-7 [16820562.001]
  • [Cites] Tissue Eng. 2006 Jul;12(7):1787-98 [16889509.001]
  • [Cites] Liver Int. 2006 Dec;26(10):1225-33 [17105588.001]
  • [Cites] Am J Pathol. 2006 Dec;169(6):2066-74 [17148669.001]
  • [Cites] Hepatology. 2007 Jan;45(1):31-41 [17187411.001]
  • [Cites] Hepatology. 2007 Jan;45(1):139-49 [17187413.001]
  • [Cites] Dig Liver Dis. 2007 Mar;39(3):262-6 [17270507.001]
  • [Cites] Hepatology. 2007 Mar;45(3):716-24 [17326146.001]
  • [Cites] Wound Repair Regen. 2007 May-Jun;15(3):422-9 [17537130.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1973-87 [17664288.001]
  • [Cites] Ital J Anat Embryol. 2007 Apr-Jun;112(2):93-109 [17687874.001]
  • [Cites] Dig Liver Dis. 2007 Sep;39(9):878-82 [16875890.001]
  • [Cites] Am J Pathol. 2007 Nov;171(5):1529-37 [17884967.001]
  • [Cites] Gastroenterology. 2007 Nov;133(5):1579-91 [17983805.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1313-23 [11290549.001]
  • [Cites] Semin Liver Dis. 2001 Aug;21(3):373-84 [11586466.001]
  • [Cites] J Hepatol. 2002 Apr;36(4):552-64 [11943430.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):336-44 [12105861.001]
  • [Cites] Hepatology. 2002 Aug;36(2):297-304 [12143037.001]
  • [Cites] Semin Cell Dev Biol. 2002 Dec;13(6):389-96 [12468238.001]
  • [Cites] Semin Cell Dev Biol. 2002 Dec;13(6):397-403 [12468239.001]
  • [Cites] Mech Dev. 2003 Jan;120(1):117-30 [12490302.001]
  • [Cites] Hepatology. 2003 Mar;37(3):632-40 [12601361.001]
  • [Cites] Hepatology. 2003 Jun;37(6):1385-94 [12774018.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11881-8 [12902545.001]
  • [Cites] Hepatology. 2004 Feb;39(2):376-85 [14767990.001]
  • [Cites] Am J Pathol. 2004 Apr;164(4):1347-59 [15039222.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8360-5 [15155906.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1739-45 [15185318.001]
  • [Cites] Cancer Res. 1978 Apr;38(4):1092-8 [76508.001]
  • [Cites] Transplantation. 1980 Dec;30(6):429-35 [7008291.001]
  • [Cites] Hepatology. 1982 Jan-Feb;2(1):77-86 [6172353.001]
  • [Cites] Mol Cell Biol. 1985 Apr;5(4):780-6 [2581126.001]
  • [Cites] Science. 1988 Jul 1;241(4861):58-62 [2898810.001]
  • [Cites] Dig Liver Dis. 2009 Jul;41(7):455-62 [19403350.001]
  • [Cites] Mech Dev. 2009 Aug-Sep;126(8-9):665-76 [19527784.001]
  • [Cites] Hepatology. 2010 Apr;51(4):1401-9 [20054870.001]
  • [Cites] Lab Invest. 2010 Aug;90(8):1199-208 [20440274.001]
  • [Cites] Cancer Res. 1989 Mar 15;49(6):1554-61 [2647288.001]
  • [Cites] Am J Pathol. 1989 Jun;134(6):1347-63 [2474256.001]
  • [Cites] Cancer Res. 1991 Feb 15;51(4):1308-17 [1997169.001]
  • [Cites] Dig Dis Sci. 1991 May;36(5):653-8 [2022167.001]
  • [Cites] Ontogenez. 1990 Nov-Dec;21(6):625-32 [2095484.001]
  • [Cites] Lab Invest. 1994 Apr;70(4):511-6 [7513770.001]
  • [Cites] FASEB J. 1995 Nov;9(14):1396-400 [7589980.001]
  • (PMID = 21074735.001).
  • [ISSN] 1878-0814
  • [Journal-full-title] Progress in molecular biology and translational science
  • [ISO-abbreviation] Prog Mol Biol Transl Sci
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK058614-08; United States / NIDDK NIH HHS / DK / R01 DK065096; United States / NIDDK NIH HHS / DK / DK065096-04S1; United States / NIDDK NIH HHS / DK / R01 DK065096-06; United States / NIDDK NIH HHS / DK / R01 DK058614-08; United States / NIDDK NIH HHS / DK / DK065096-06; United States / NIDDK NIH HHS / DK / R01 DK058614; United States / NIDDK NIH HHS / DK / R01 DK065096-04S1
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS303015; NLM/ PMC3122078
  •  go-up   go-down


95. Vitale A, Guarini A, Ariola C, Meloni G, Perbellini O, Pizzuti M, De Gregoris C, Mettivier V, Pastorini A, Pizzolo G, Vignetti M, Mandelli F, Foà R: Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial. Haematologica; 2007 Mar;92(3):342-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial.
  • BACKGROUND AND OBJECTIVES: The prognostic value of myeloid antigen (MyAg) expression in adult acute lymphoblastic leukemia (ALL) is still controversial.
  • The aim of this study was to correlate the expression of MyAg with clinical, hematologic and biological parameters, and to analyze the impact on response to treatment and prognosis in a large series of adult ALL uniformly characterized and treated.
  • DESIGN AND METHODS: We analyzed the expression of the MyAg CD13 and/or CD33 in a cohort of 377 adult patients with de novo ALL enrolled and treated in the GIMEMA ALL 0496 protocol.
  • RESULTS: MyAg expression was documented in 35% of the 377 adult ALL cases analyzed.
  • No difference was found with regard to clinical features at presentation; a difference was found only for white cell count (p=0.03), percentage of peripheral blasts (p=0.004) and platelet count (p=0.004).
  • [MeSH-major] Antigens, CD / biosynthesis. Antigens, CD13 / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. Antigens, Neoplasm / biosynthesis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Randomized Controlled Trials as Topic / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blood Cell Count. Burkitt Lymphoma / blood. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / mortality. Burkitt Lymphoma / radiotherapy. Cell Lineage. Cohort Studies. Combined Modality Therapy. Cranial Irradiation. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Disease-Free Survival. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Female. Humans. Immunophenotyping. Leukemia-Lymphoma, Adult T-Cell / blood. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / mortality. Leukemia-Lymphoma, Adult T-Cell / radiotherapy. Male. Middle Aged. Multicenter Studies as Topic / statistics & numerical data. Prognosis. Radiotherapy, Adjuvant. Remission Induction. Sialic Acid Binding Ig-like Lectin 3

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17339183.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antigens, Neoplasm; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 04079A1RDZ / Cytarabine; EC 3.4.11.2 / Antigens, CD13; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


96. Kühnl A, Gökbuget N, Stroux A, Burmeister T, Neumann M, Heesch S, Haferlach T, Hoelzer D, Hofmann WK, Thiel E, Baldus CD: High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. Blood; 2010 May 6;115(18):3737-44
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia.
  • Overexpression of BAALC is an adverse prognostic factor in adults with cytogenetically normal acute myeloid leukemia and T-cell acute lymphoblastic leukemia (ALL).
  • Here, we analyzed the prognostic significance of BAALC in B-precursor ALL.
  • BAALC MRNA expression was determined in 368 primary adult B-precursor ALL patients enrolled on the 06/99 and 07/03 GMALL trials.
  • Higher BAALC expression (T3 vs T2 vs T1) was associated with higher age (P < .001), a higher white blood cell count (P = .008), CD34 (P = .001), BCR-ABL (P < .001), and MLL-AF4 (P < .001).
  • Gene-expression profiling revealed an up-regulation of stem cell markers and genes involved in chemoresistance (TSPAN7 and LYN) in the high BAALC group.
  • Determination of BAALC might contribute to risk assessment of molecularly undefined adult B-precursor ALL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / metabolism. Drug Resistance, Neoplasm. Neoplasm Proteins / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Gene Expression Profiling. Humans. Immunophenotyping. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / metabolism. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2010 May 6;115(18):3649-50 [20448115.001]
  • (PMID = 20065290.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BAALC protein, human; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


97. Rupnik M: All together now: exocytose or fail. Islets; 2009 Jul-Aug;1(1):78-80
MedlinePlus Health Information. consumer health - Diabetes Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Optimal cell-to-cell electrical coupling through Connexin36 (Cx36) seems to ensure coordinated plasma membrane depolarization pattern and insulin exocytosis.
  • The complex structure and coordinated action develop after birth during fast hypertrophy and hyperplasia of the endocrine tissue and are maintained throughout adult life.
  • In majority of cases the islet structure is lost after extensive beta-cell death in long-term hyperglycemia.
  • [MeSH-minor] Adult. Animals. Connexins / genetics. Connexins / metabolism. Connexins / physiology. Humans. Islets of Langerhans / metabolism. Islets of Langerhans / physiology

  • MedlinePlus Health Information. consumer health - Diabetes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Diabetes. 2007 Apr;56(4):1078-86 [17395748.001]
  • (PMID = 21084853.001).
  • [ISSN] 1938-2022
  • [Journal-full-title] Islets
  • [ISO-abbreviation] Islets
  • [Language] eng
  • [Publication-type] Comment; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Connexins; 0 / Insulin; 0 / connexin 36
  •  go-up   go-down


98. Warnatz K, Salzer U, Rizzi M, Fischer B, Gutenberger S, Böhm J, Kienzler AK, Pan-Hammarström Q, Hammarström L, Rakhmanov M, Schlesier M, Grimbacher B, Peter HH, Eibel H: B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc Natl Acad Sci U S A; 2009 Aug 18;106(33):13945-50
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans.
  • B-cell survival depends on signals induced by B-cell activating factor (BAFF) binding to its receptor (BAFF-R).
  • In mice, mutations in BAFF or BAFF-R cause B-cell lymphopenia and antibody deficiency.
  • Without BAFF-R, B-cell development is arrested at the stage of transitional B cells and the numbers of all subsequent B-cell stages are severely reduced.
  • They also did not mount a T-independent immune response against pneumococcal cell wall polysaccharides but only one BAFF-R-deficient sibling developed recurrent infections.
  • [MeSH-major] B-Cell Activation Factor Receptor / deficiency. B-Cell Activation Factor Receptor / genetics. Immunologic Deficiency Syndromes / genetics
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Amino Acid Sequence. B-Lymphocytes / metabolism. Cohort Studies. Family Health. Female. Homozygote. Humans. Male. Middle Aged. Molecular Sequence Data


99. Hundsdoerfer P, Dietrich I, Schmelz K, Eckert C, Henze G: XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL. Pediatr Blood Cancer; 2010 Aug;55(2):260-6
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL.
  • BACKGROUND: Resistance to glucocorticoid induced apoptosis is one of the major risk factors for relapse and poor outcome in childhood acute lymphoblastic leukemia (ALL).
  • In patients with T-cell ALL, poor prednisone response was associated with increased XIAP expression (median: 2.8 in good vs. 5.8 in poor responders; P = 0.005).
  • Similarly, T-cell ALL patients suffering adverse events showed higher initial XIAP levels than patients in continuous complete remission (CCR) (median: 2.7 in patients in CCR vs. 5.6 in patients suffering adverse events; P = 0.007).
  • The association with poor in vivo glucocorticoid response and outcome in T-cell ALL suggests XIAP inhibition as a promising novel approach for the treatment of resistant ALL.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Glucocorticoids / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. X-Linked Inhibitor of Apoptosis Protein / genetics
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Bone Marrow Cells / pathology. Bone Marrow Examination. Child. Drug Resistance. Female. Humans. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Male. Monocytes / pathology. Pharmacogenetics. Prognosis. RNA, Messenger / analysis. Treatment Outcome. Up-Regulation

  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20582956.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / RNA, Messenger; 0 / X-Linked Inhibitor of Apoptosis Protein
  •  go-up   go-down


100. Weisberger J, Gorczyca W, Kinney MC: CD56-positive large B-cell lymphoma. Appl Immunohistochem Mol Morphol; 2006 Dec;14(4):369-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD56-positive large B-cell lymphoma.
  • CD56 (NCAM), a neural adhesion molecule, is normally expressed on natural killer cells and subsets of T cells and is commonly seen on hematolymphoid neoplasms such as plasma cell myeloma and acute myelogenous leukemia.
  • It is uncommon in B-cell lymphoma.
  • From 2001 to 2003 a cohort of 20 cases of CD56 B-cell lymphomas was identified by flow cytometry (<0.5% of all B-cell lymphomas studied) during a 2-year period.
  • These CD56 B-cell lymphomas may represent a new subset of large B-cell lymphoma.
  • The relationship of cells with this antigenic profile to normal B-cell differentiation is explored.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122631.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down






Advertisement